The global personalized medicine (PM) market size is expected to reach USD 3.18 trillion by 2025 registering a CAGR of 10.6% over the forecast period…
NEW YORK, Oct. 21, 2019 /PRNewswire/ --
Personalized Medicine Market Size, Share & Trends Analysis By Product (Personalized Medical Care, Therapeutics, Personalized Nutrition & Wellness), By Region (Asia Pacific, Europe, North America), And Segment Forecasts, 2019 - 2025
Read the full report: https://www.reportlinker.com/p05807253/?utm_source=PRN
The global personalized medicine (PM) market size is expected to reach USD 3.18 trillion by 2025 registering a CAGR of 10.6% over the forecast period. Growing number of approved companion diagnostics and biomarker products have been proved promising avenues for the development of advanced precision diagnostic tests. Several personalized diagnostics and therapeutic products based on companion diagnostics are under clinical trials and development pipelines, which also add an incremental opportunity to accelerate this market.
Gene therapies are widely utilized to diagnose both chronic and genetic disorders according to individual's genetic makeup.Growing adoption of gene sequencing and data analytics technologies is anticipated to escalate precision medicine market growth.
Decreasing cost of whole genome sequencing, advancement in cell biology sector, and the development of "Human Genome Project" are several other factors influencing the demand for gene therapy hence, boosting the overall market. Moreover, key leaders are undergoing numerous strategic developments to launch novel personalized products, which will also contribute to the market expansion.
For instance, in September 2018, Vertex Pharmaceuticals collaborated with Genomics for the delivery of precision medicine based on individual's genetic differences and lifestyle. Similarly, in January 2018, Foundation Medicine collaborated with European Organization for Research and Treatment of Cancer (EORTC) to facilitate Foundation's comprehensive genomic profiling to across personalized medicine and clinical trial enrolment.
Further key findings from the study suggest: PM therapeutics is projected to register the fastest CAGR over the forecast period owing to the development of high-capacity rapid sequencing platforms for medical therapies Reduction in sequencing cost leads to an expected growth of genomic sequencing and genetic research, thus contributing to lucrative opportunities for genomic medicine Asia Pacific is projected to be the fastest-growing regional market due to rising number of collaborative initiatives between eastern and western market leaders Chinese personalized medicine market is benefitted due to initiatives implemented by the Chinese government and reimbursements for disease treatment Prominent companies include GE Healthcare; Illumina, Inc.; Asuragen, Inc.; Abbott Laboratories; Dako A/S; Exact Science Corp.; and Biogen, Inc.
Read the full report: https://www.reportlinker.com/p05807253/?utm_source=PRN
About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001
SOURCE Reportlinker
See original here:
The global personalized medicine (PM) market size is expected to reach USD 3.18 trillion by 2025 registering a CAGR of 10.6% over the forecast period...
Recommendation and review posted by Bethany Smith
Growth of Age-Related Macular Degeneration (AMD) Therapeutics Market to be Impacted by the Development of Gene Therapy for AMD | Technavio – Yahoo…
LONDON--(BUSINESS WIRE)--
The market will accelerate at a CAGR of over 8% between 2019-2023
The report, global age-related macular degeneration (AMD) therapeutics market has been added to Technavios catalog. It provides a comprehensive analysis of the market, including its global and regional market share as well as market segmentation based on type and geography for the forecast period 2019-2023.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191021005715/en/
To learn more about the global trends impacting the future of market research: Download Free Sample Report
This report on the age-related macular degeneration (AMD) therapeutics market includes:
Age-related macular degeneration (AMD) therapeutics market analysis and forecast 2019-2023: Features
Competitive landscape
Market segmentation
Type
Geography
Market drivers
Market trends
Market challenges
Five forces analysis
Market landscape
Market sizing & forecast
Age-Related Macular Degeneration (AMD) Therapeutics Market 2019-2023: Competitive Landscape
Vendors covered
Vendor classification
Amgen Inc.
Bausch Health Companies, Inc.
F. Hoffmann-La Roche Ltd.
Novartis AG
Regeneron Pharmaceuticals Inc.
Age-Related Macular Degeneration (AMD) Therapeutics Market 2019-2023: Geographic Landscape
North America - Market size and forecast 2018-2023
Europe - Market size and forecast 2018-2023
Asia - Market size and forecast 2018-2023
ROW - Market size and forecast 2018-2023
Key leading countries
Age-Related Macular Degeneration (AMD) Therapeutics Market 2019-2023: Type Landscape
Register for a free trial today and gain instant access to 10,000+ market research reports. Technavio's SUBSCRIPTION platform
High prevalence of AMD will drive the age-related macular degeneration (AMD) therapeutics market
The prevalence of AMD is increasing significantly, owing to the presence of high-risk factors such as aging, smoking, high cholesterol, and high blood pressure. Moreover, despite the high prevalence of AMD, no approved therapies are available in the market for the treatment of the condition. Thus, the high prevalence coupled with the huge unmet medical need of dry AMD are expected to drive market growth during the forecast period.
Story continues
Development of gene therapy for AMD An emerging trend in the osteoporosis market
At present, only a few drugs are approved for the treatment of AMD. However, the side effects associated with them are very severe, and the majority of them act against VEGF only. Hence, there is a huge unmet need for safe and novel drugs to treat AMD. The currently available anti-VEGF therapies require repetitive and inconvenient intraocular injections. Hence, several companies are working on novel drugs to combat AMD, among which gene therapy is expected to cure the disease effectively. Hence, the development of gene therapy is expected to be a positive trend for the global AMD therapeutics market.
Other Key Topics Covered in the Report are:
MARKET LANDSCAPE
MARKET SIZING
Get Full Report: https://www.technavio.com/report/age-related-macular-degeneration-therapeutics-market-industry-analysis
CUSTOMER LANDSCAPE
DECISION FRAMEWORK
DRIVERS AND CHALLENGES
Market drivers
Market challenges
Market Trends
Technavio also offers Custom Research services providing focused, comprehensive, and tailored research.
For More Information Click Here
Browse Related Healthcare Reports:
Global Plethysmograph Market: The global plethysmograph market is forecast to grow at a CAGR of over 3% during the period 2019-2023. The plethysmograph market size will increase by USD 14.86 million during the forecast period of 2019-2023.
Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Market: The global vascular endothelial growth factor (VEGF) inhibitors market is forecast to grow at a CAGR of over 8% during the period 2019-2023. The vascular endothelial growth factor (VEGF) inhibitors market size will increase by USD 10.2 billion during the forecast period of 2019-2023.
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavios report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191021005715/en/
See the original post here:
Growth of Age-Related Macular Degeneration (AMD) Therapeutics Market to be Impacted by the Development of Gene Therapy for AMD | Technavio - Yahoo...
Recommendation and review posted by Bethany Smith
Cesca Therapeutics Forms Joint Venture with Healthbanks Biotech (USA) to Provide Immune Cell Banking and Cell Processing Services – BioSpace
ImmuneCyte to Begin Operations in Fourth Quarter of 2019
RANCHO CORDOVA, Calif., Oct. 22, 2019 /PRNewswire/ -- Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell processing and autologous cell therapies for regenerative medicine, and ThermoGenesis, its wholly owned device subsidiary, today announced that the company has entered into a definitive joint venture agreement with HealthBanks Biotech (USA) Inc., one of the world's leading stem cell bank networks, to commercialize its proprietary cell processing platform, CAR-TXpress, for use in immune cell banking as well as for cell-based contract development and manufacturing services (CMO/CDMO). The joint venture will be named ImmuneCyte Life Sciences Inc. ("ImmuneCyte") and is expected to officially launch during the fourth quarter of 2019.
Under terms of the agreement, ImmuneCyte will initially be owned 80% by HealthBanks Biotech and 20% by Cesca. Cesca will contribute to ImmuneCyte exclusive rights to use ThermoGenesis' proprietary cell processing technology for the immune cell banking business and non-exclusive rights for other cell-based contract development and manufacturing services. Cesca will also contribute its clinical development assets to the joint venture, as the company has decided to discontinue these activities in order to focus exclusively on the device business.
Once operational, ImmuneCyte will be among the first immune cell banks in the U.S. to provide clients with the opportunity to bank their own healthy immune cells for future use as a resource for cell-based immunotherapies, such as dendritic cell and chimeric antigen receptor (CAR) T-cell therapies. ImmuneCyte will utilize ThermoGenesis' proprietary CAR-TXpress platform which allows for the isolation of different components from 200 ml of blood in cGMP compliant, closed system. Given that the CAR-TXpress platform can increase cell processing efficiency by up to 16-fold as compared with the traditional, labor-intensive ficoll gradient centrifugation-based cell processing method, ImmuneCyte is expected to offer customers an unparalleled competitive advantage, including an ability to store their own immune cells at a tangibly lower cost.
"The ImmuneCyte joint venture will be paramount to the execution of our strategy to become a preferred cell processing and manufacturing solution provider in the cell and gene therapy field," said Dr. Chris Xu, Chairman and Chief Executive Officer of Cesca Therapeutics. "CAR-T therapeutic research is advancing rapidly. Partnering with HealthBanks Biotech, one of the foremost stem cell bank networks, with an experienced team and an established global infrastructure, will offer customers the ability to preserve younger, healthier and uncontaminated immune cells for potential future use. By applying our proprietary CAR-TXpress technology to immune cell banking and other CDMO cellular manufacturing services, we will allow for the manufacture and production of more effective and less costly immunotherapies."
In 2017, the U.S. Food and Drug Administration (FDA) approved two CAR-T cell therapies, under breakthrough designation, for the treatment of advanced B cell leukemia and lymphomas. Both use autologous (a patient's own) immune T cells to fight cancer and have reported an over 80% response rate in the "no-option" patient group, for those who have failed both chemo- and radiation therapies. This has helped to spur massive global interest for the development of additional CAR-T immunotherapies1. By the end of September 2019, there were over 800 CAR-T cell clinical trials registered on the http://www.clinicaltrials.gov website, targeting a wide variety of blood cancers and solid tumors.
Although highly effective, several recent studies on the eligibility of patients to enroll in CAR-T clinical trials showed that as many as 30-50% of cancer patients may not be eligible to enroll or to get sufficient CAR-T cells manufactured for the therapy. Reasons may include: (1) the function of the immune system declines with age and can be negatively affected by other medical conditions, (2) most standard cancer therapies, such as chemotherapy and radiation, destroy the immune system, and (3) in many cases of advanced cancer, cancer cells will enter circulation, invade and interfere with the body's natural production of immune cells. According to a recently reported JULIE trial, a CAR-T clinical trial in relapsed or refractory diffuse large B-cell lymphoma (DLBCL), one-third of the 238 screened patients failed to be enrolled, and more than half of the 238 failed to receive the intended CAR-T therapy2,3. ImmuneCyte will offer customers the ability to preserve younger, healthier and uncontaminated immune cells, for potential future use in advanced cancer immunotherapy.
About HealthBanks Biotech (USA) Inc.HealthBanks Biotech, headquartered in Irvine, CA, is one of the leading stem cell bank networks in the world and offers services globally through its sister companies located in the United States and other regions and nations. HealthBanks Biotech is accredited by the FDA, AABB, and CAP. The HealthBanks Biotech group was originally founded in 2001 with a vision that stem cells and cell and gene therapies could transform modern medicine. HealthBanks Biotech is a subsidiary of Boyalife Group, Inc. (USA), an affiliate of Boyalife (Hong Kong) Limited, the largest stockholder of Cesca. For more information about HealthBanks Biotech (USA) Inc., please visit: http://www.healthbanks.us.
About ImmuneCyte Life Sciences Inc.ImmuneCyte will provide clients with the opportunity to bank their own immune cells when the cells are "healthy and unaffected" as a future resource for cellular immunotherapies, such as CAR-T. ImmuneCyte utilizes a proprietary CAR-TXpress platform, a GMP compliant close-system capable of automated separating and cryopreserving different components from blood. For more information about ImmuneCyte Life Sciences Inc., please visit: http://www.immunecyte.com.
About Cesca Therapeutics Inc.Cesca Therapeutics develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. Its device division, ThermoGenesis develops, commercializes and markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. The Company has developed a semi- automated, functionally closed CAR-TXpress platform to streamline the manufacturing process for the emerging CAR-T immunotherapy market. For more information about Cesca and ThermoGenesis, please visit: http://www.cescatherapeutics.com.
Company Contact:Wendy Samford916-858-5191ir@thermogenesis.com
Investor Contact:Paula Schwartz, Rx Communications917-322-2216pschwartz@rxir.com
References:
1. Facts About Chimeric Antigen Receptor (CAR) T-Cell Therapy, Leukemia and Lymphoma Society (2018). https://www.lls.org
2. Updated Analysis of JULIET Trial: Tisagenlecleucel in Relapsed or Refractory DLBCL (2018).
3. Eligibility Criteria for CAR-T Trials and Survival Rates in Chemorefractory DLBCL. Journal of Clinical Pathways (2018).
View original content:http://www.prnewswire.com/news-releases/cesca-therapeutics-forms-joint-venture-with-healthbanks-biotech-usa-to-provide-immune-cell-banking-and-cell-processing-services-300942618.html
SOURCE Cesca Therapeutics Inc.
Company Codes: NASDAQ-SMALL:KOOL
Recommendation and review posted by Bethany Smith
Abeona Therapeutics Announces Presentations at the 27th European Society of Gene and Cell Therapy (ESGCT) Congress – BioSpace
NEW YORK and CLEVELAND, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the presentations of data from the Transpher A Study, the Companys ongoing Phase 1/2 clinical trial evaluating ABO-102 for the treatment of Sanfilippo syndrome type A (MPS IIIA), and research updates from its library of novel AIMTM adeno-associated virus (AAV) capsids at the 27th European Society of Gene and Cell Therapy (ESGCT) Congress, to be held October 22-25, 2019 in Barcelona, Spain.
The data will be presented as follows:
Safety, Tolerability, Biopotency and Neurocognitive Data of ABO-102 in Transpher A, an Open-Label, Multicenter, Single-Dose, Dose-Escalation, Phase 1/2 Clinical Trial in Sanfilippo Syndrome type A (Mucopolysaccharidosis IIIA)Oral Presentation #039Presenter: Maria Jose de Castro, M.D., Hospital Universitario Santiago de CompostelaSession 4c: Metabolic and Genetic DiseasesDate/Time: Friday, October 25, 2019, 9:00 a.m. to 11:00 a.m. CESTLocation: Room 112
Novel AAV Capsids Show Increased Evasion to Neutralizing Antibodies Against Natural SerotypesPoster #P347Session Title: Poster Session IDate/Time: Wednesday, October 23, 2019, 1:00 p.m. to 3:00 p.m. CESTLocation: Multipurpose Hall
Development of an Improved Novel AAV Capsids for Intramuscular DeliveryPoster #P027Session Title: Poster Session IDate/Time: Wednesday, October 23, 2019, 1:00 p.m. to 3:00 p.m. CESTLocation: Multipurpose Hall
Novel AAV Capsids for Delivery to the Retina by Intravitreal AdministrationPoster #P009Session Title: Poster Session IDate/Time: Wednesday, October 23, 2019, 1:00 p.m. to 3:00 p.m. CESTLocation: Multipurpose Hall
Development of a Novel AAV Capsid with Improved PNS Tropism for Treating Pompe Disease by Intravenous AdministrationPoster #P007Session Title: Poster Session IDate/Time: Wednesday, October 23, 2019, 1:00 p.m. to 3:00 p.m. CESTLocation: Multipurpose Hall
About Abeona Therapeutics Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene and cell therapies for serious diseases. The Companys clinical programs include EB-101, its autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa, as well as ABO-102 and ABO-101, novel AAV9-based gene therapies for Sanfilippo syndrome types A and B (MPS IIIA and MPS IIIB), respectively. The Companys portfolio of AAV9-based gene therapies also features ABO-202 and ABO-201 for CLN1 disease and CLN3 disease, respectively. Its preclinical assets include ABO-401, which uses the novel AIM AAV vector platform to address all mutations of cystic fibrosis. Abeona has received twenty regulatory designations from the FDA and EMA for its pipeline candidates. For more information, visit http://www.abeonatherapeutics.com.
Forward-Looking StatementsThis press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. These statements include statements about the Companys clinical trials and its products and product candidates, future regulatory interactions with regulatory authorities, as well as the Companys goals and objectives. We have attempted to identify forward looking statements by such terminology as may, will, believe, estimate, expect, and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances), which constitute and are intended to identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, numerous risks and uncertainties, including but not limited to continued interest in our rare disease portfolio, our ability to enroll patients in clinical trials, the outcome of any future meetings with the U.S. Food and Drug Administration or other regulatory agencies, the impact of competition, the ability to secure licenses for any technology that may be necessary to commercialize our products, the ability to achieve or obtain necessary regulatory approvals, the impact of changes in the financial markets and global economic conditions, risks associated with data analysis and reporting, and other risks as may be detailed from time to time in the Companys Annual Reports on Form 10-K and quarterly reports on Form 10-Q and other periodic reports filed by the Company with the Securities and Exchange Commission. The Company undertakes no obligation to revise the forward-looking statements or to update them to reflect events or circumstances occurring after the date of this presentation, whether as a result of new information, future developments or otherwise, except as required by the federal securities laws.
Investor Contact:Sofia WarnerSenior Director, Investor RelationsAbeona Therapeutics+1 (646) 813-4710swarner@abeonatherapeutics.com
Media Contact:Scott SantiamoDirector, Corporate CommunicationsAbeona Therapeutics+1 (718) 344-5843ssantiamo@abeonatherapeutics.com
View original post here:
Abeona Therapeutics Announces Presentations at the 27th European Society of Gene and Cell Therapy (ESGCT) Congress - BioSpace
Recommendation and review posted by Bethany Smith
GenSight Biologics Reports its Cash Position as of September 30, 2019 and Provides Operational Update – Business Wire
PARIS--(BUSINESS WIRE)--Regulatory News:
GenSight Biologics (Paris:SIGHT)(Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash position as of September 30, 2019, and provided recent operational updates.
Cash and cash equivalents
GenSight Biologics cash and cash equivalents totaled 5.1 million as of September 30, 2019, compared to 14.3 million as of June 30, 2019. This amount does not include a 4.3 million reimbursement of the 2018 Research Tax Credit, expected in the coming days. Including this impending reimbursement, cash and cash equivalents would be 9.4 million as of September 30, 2019.
The cash burn in the first three quarters of 2019 principally reflects the final steps of pharmaceutical development for GS010 in preparation for a marketing authorization filing in Europe. These are mainly preparatory activities to ensure manufacturing readiness to commercialize under Good Manufacturing Practices (GMP).
In line with our expectations and including the impending reimbursement of the 2018 Research Tax Credit, we are fully financed until the end of the first quarter of 2020, commented Thomas Gidoin, Chief Financial Officer of GenSight Biologics. We have been actively working on a financing transaction in the past weeks, favoring less dilutive options, and expect to be able to announce a closing shortly.
Clinical Development of GS010
Results at 96 weeks of the RESCUE Phase III clinical trial evaluating the efficacy and safety of a single intravitreal injection of GS010 in subjects with LHON due to the ND4 mutation with an onset of vision loss up to 6 months were reported in September 2019. This last set of results showed a durable bilateral improvement in visual acuity of 25 ETDRS letters equivalent versus nadir in GS010-treated eyes. These results from RESCUE show a remarkable correspondence with those from the REVERSE trial, which studied the treatment of subjects at 6 to 12 months after onset of vision loss.
In a natural history study conducted by Santhera1, 28% of subjects with the G11778A-ND4 mutation achieved a spontaneous clinically relevant recovery (CRR) from nadir in at least one eye. By comparison, 63% of RESCUE subjects achieved this definition of CRR in at least one eye at Week 96, showing a clear superiority to natural history. A similar comparison for REVERSE subjects reveals a much higher rate of CRR (78%) from nadir compared to natural history.
GenSight also reported results from a non-clinical study to investigate the local biodistribution of GS010. In this study, tissue samples from the non-injected eye of monkeys that had been unilaterally injected with GS010 were found to contain GS010 DNA three months after injection, indicating the expression of the therapeutic gene in the uninjected contralateral eye. These findings support the mechanism for bilateral visual improvement with unilateral GS010 gene therapy, which was consistently observed in LHON subjects in the REVERSE and RESCUE Phase III trials.
Regulatory Pathway of GS010
GenSight is planning to schedule a pre-submission meeting with the EMA in early 2020 and expects to submit an application for marketing approval in Europe in the third quarter of 2020.
An End of Phase II meeting with the U.S. Food and Drug Administration (FDA) was requested as planned, which the agency has now confirmed for December 19, 2019.
We strongly believe that the remarkable results from REVERSE and RESCUE, showing a clinically significant and durable bilateral improvement of vision, and demonstrating clear superiority to natural history, are a compelling core for our marketing authorization application in Europe, commented Bernard Gilly, co-founder and Chief Executive Officer of GenSight Biologics. The demonstration of GS010 DNA presence in the uninjected contralateral eye now provides a powerful scientific rationale to support bilateral improvement. We are eager to meet with regulatory agencies in the next few weeks to discuss these major findings.
Number of outstanding shares
As of September 30, 2019, GenSight Biologics number of outstanding shares was 29,028,291 ordinary shares.
GenSight Biologics will report its cash position as of December 31, 2019 on January 21, 2020.
GenSight will host a conference call today, October 22, 2019, at 9:30am CEST in French, and at 2.30pm CEST (8.30am EST) in English, to further discuss this operational update.
Conference call in French
Dial-in numbers:
France: +33 (0) 1 7037 7166Password: GenSight Franais
Conference call in English
Dial-in numbers:
United States: +1 212 999 6659France: +33 (0) 1 7037 7166United Kingdom: +44 (0) 20 3003 2666Password: GenSight English
A replay of the calls will be available using the following dial-in numbers:
France: +33 (0) 1 7037 7166United Kingdom (standard international access): +44 (0) 20 3003 2666Code: 5645038#
About GenSight Biologics
GenSight Biologics S.A. is a clinical-stage biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics lead product candidate, GS010, is in Phase III trials in Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible blindness in teens and young adults. Using its gene therapy-based approach, GenSight Biologics product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.
1 Magda et al (2019), Natural History of Lebers Hereditary Optic Neuropathy (LHON): Findings from a Large Patient Cohort, Poster presented at NANOS March 16-21, 2019; Poster Session II: Scientific Advancements; Poster: 163
Original post:
GenSight Biologics Reports its Cash Position as of September 30, 2019 and Provides Operational Update - Business Wire
Recommendation and review posted by Bethany Smith
SmartPharm Therapeutics Appoints John T. Potts, MD, DSc, to Board of Directors – BioSpace
CAMBRIDGE, Mass., Oct. 21, 2019 /PRNewswire/ -- SmartPharm Therapeutics, a preclinical-stage pharmaceutical company focused on developing next-generation, non-viral gene therapies for the treatment of rare diseases, today announced the appointment of John T. Potts, MD, DSc, to its Board of Directors. Dr. Potts' distinguished, five-decade career in healthcare and the life sciences spans medical disciplines and encompasses ground-breaking preclinical and clinical research.
"We are honored to welcome John to the SmartPharm Board. His acumen and experience will be invaluable to the Company during its journey into the clinic," said Steve Gorlin, Chairman of the Board for SmartPharm.
"I am excited to be joining SmartPharm Therapeutics and believe the Company's approach to next-generation, non-viral, gene-encoded protein therapies holds significant potential to impact medicine in a similar manner to biologics, while eliminating their onerous manufacturing and delivery systems," commented Dr. Potts.
Dr. Potts is the Jackson Distinguished Professor of Clinical Medicine at the Massachusetts General Hospital (MGH) and Harvard Medical School. After completing his MD at the University of Pennsylvania and internship and residency at MGH, he worked at the National Institutes of Health for almost a decade, studying protein chemistry with Nobel laureate Christian Anfinsen. He returned to MGH as Chief of Endocrinology in 1968 where he subsequently served as Director of Research, Chairman of the Department of Medicine and Physician-in-Chief. An internationally-recognized authority on calcium metabolism and the hormonal mechanisms that govern it, he has been a pioneer in identifying the chemistry and biology of clinical disorders of bone and mineral ion metabolism.
Dr. Potts has played an active role in the life sciences industry. He is a founder of Radius Health, Inc., a biopharmaceutical company focused on developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology, where he currently serves as a Scientific Advisory Board Member. He has also served on advisory boards with MPM Capital and HealthCare Ventures. He has previously held board of directors positions with Cell Genesys, Zeltiq Aesthetics, Genentech and NantKwest.
An author on over 500 publications, his honors and awards include the Association of Professors of Medicine's Robert H. Williams, MD, Distinguished Chair of Medicine Award; the Biomedical Science Career Program Hope Award; the Endocrine Society's Fred Konrad Koch Award; and the American Society for Bone and Mineral Research's William F. Neumann Award. He holds active and honorary memberships in a number of scientific and professional organizations including the National Academy of Medicine, American Academy of Arts and Sciences, and the National Academy of Sciences.
About SmartPharm Therapeutics
SmartPharm Therapeutics Inc. is a privately-held, development-stage pharmaceutical company focused on developing next-generation, non-viral gene therapies for the treatment of serious or rare diseases with the vision of creating "biologics from within." The Company is currently developing a novel pipeline of non-viral, gene-encoded proteins for the treatment of conditions that require enzyme replacement therapy and tissue restoration. SmartPharm commenced operations in 2018 and is headquartered in Cambridge, MA, USA. For more information, please visit http://www.smartpharmtx.com.
View original content:http://www.prnewswire.com/news-releases/smartpharm-therapeutics-appoints-john-t-potts-md-dsc-to-board-of-directors-300941723.html
SOURCE SmartPharm Therapeutics
Read more:
SmartPharm Therapeutics Appoints John T. Potts, MD, DSc, to Board of Directors - BioSpace
Recommendation and review posted by Bethany Smith
ISCT forms cell and gene therapy sector-wide coalition to combat the rise of unproven commercial cell banking services – PharmiWeb.com
Vancouver, Canada, October 21, 2019 ISCT, the International Society for Cell and Gene Therapy, the global professional society of clinicians, researchers, regulatory specialists, technologists and industry partners in the cell and gene therapy sector, today announces it has formed a global consortium of a wide range of leading professional and education societies to combat the rise in the number of unproven commercial cell banking services. Full details of the statement can be foundhere.
The consortium partners include the International Society for Stem Cell Research (ISSCR), Society for Immunotherapy of Cancer (SITC), American Society for Transplantation and Cellular Therapy (ASTCT),American Society of Gene & Cell Therapy (ASGCT), European Society for Blood and Marrow Transplantation (EBMT), Foundation for the Accreditation of Cellular Therapy (FACT), Joint Accreditation Committee ISCT-EBMT (JACIE) and the Forum for Innovative Regenerative Medicine (FIRM).
The consortium has been formed following ISCT issuingpatient advice and concern on unproven T-cell preservation services on August 7, 2019. These services include the banking of T-cells, dental cells and cells for the derivation of induced pluripotent stem cells for potential therapeutic uses.
The joint statement from ISCT and the consortium partners includes an agreement on a number of key points. Commercial cell banking services are not supported by current scientific evidence, as opposed to the range of cell therapies such as CAR-T therapies, that follow established approval processes. Additionally, cell banking services cannot claim to know that the cells they preserve today could ever be appropriate for clinical use, could be used by manufacturers, or meet the requirements of many national and international regulatory agencies. As a result, there is no clear pathway to legitimate clinical use. All parties agree offering these services commercially to patients is thus premature, misleading, and drives false hope.
In addition, the ISCT joint statement makes clear that patients, being misled by these services, are thus prevented from giving a full and valid informed consent. Cell banking companies mislead patients in a number of ways, including using tokens of scientific legitimacy that suggest a stronger scientific basis than currently exists. These tokens include endorsements from individuals or scientific advisory boards that might not fully endorse the specific products, links to scientific articles, and references to ongoing clinical trials.
ISCTs raison detre is to lead the industry in supporting scientifically validated cell and gene therapies. As a result, ISCT will continue to welcome all innovations, including cell banking approaches, that increase the number of patients who can benefit from these therapies, said Bruce Levine,President-Elect, ISCT and one of the inventors of CAR-T therapies.However, ISCT also leads industry action on unproven cell therapies and services in the cell and gene sector. This is why ISCT has forged a consortium throughout the industry against the marketing of speculative cell banking services that do not have appropriate pre-clinical, and clinical evidence and a plausible pathway to the clinical use of banked cells. We collectively believe these banks have the potential to be detrimental to the future development of cell and gene therapies.
About ISCT
Established in 1992, ISCT, the International Society for Cell and Gene Therapy is a global society of clinicians, regulators, researchers, technologists and industry partners with a shared vision to translate cellular therapy into safe and effective therapies to improve patients lives worldwide.
ISCT is the global leader focused on pre-clinical and translational aspects of developing cell-based therapeutics, thereby advancing scientific research into innovative treatments for patients. ISCT offers a unique collaborative environment that addresses three key areas of translation: Academia, Regulatory and Commercialization. Through strong relationships with global regulatory agencies, academic institutions and industry partners, ISCT drives the advancement of research into standard of care.
Comprised of over 1,500 cell therapy experts across five geographic regions and representation from over 50 countries, ISCT members are part of a global community of peers, thought leaders and organizations invested in cell therapy translation. For more information about the society, key initiatives and upcoming meetings, please visit:
See more here:
ISCT forms cell and gene therapy sector-wide coalition to combat the rise of unproven commercial cell banking services - PharmiWeb.com
Recommendation and review posted by Bethany Smith
Tay-Sachs Disease Pipeline Insight Market Research Report 2019: by Trends, Development, Types, Therapeutics, Drugs, Clinical Trials, Competitive…
Tay-Sachs Disease Pipeline Insight Market Research 2019 report by Mart Research outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Tay-Sachs Disease pipeline landscape is provided which includes the disease overview and Tay-Sachs Disease treatment guidelines. The assessment part of the report embraces, in depth Tay-Sachs Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Tay-Sachs Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Tay-Sachs Disease Understanding
According to National Organization for Rare Disorders (NORD), Tay-Sachs disease is a rare, neurodegenerative disorder in which deficiency of an enzyme hexosaminidase A results in excessive accumulation of certain fats (lipids) known as gangliosides in the brain and nerve cells. This abnormal accumulation of gangliosides leads to progressive dysfunction of the central nervous system. This disorder is categorized as a lysosomal storage disease. Tay-Sachs disease is broken down into the classic or infantile form, the juvenile form, and the adult or late-onset form. In individuals with infantile Tay-Sachs disease, symptoms typically first appear between three and five months of age. In individuals with the late-onset form, symptoms may become apparent anytime from adolescence through the mid-30s.
Browse Full Tay-Sachs Disease Pipeline Insight Market Research Report @ https://martresearch.com/market-analysis/tay-sachs-disease-pipeline-insight/2/42159
Companies Covered in Tay-Sachs Disease Pipeline Insight Mart ResearchAxovant Gene TherapiesIntraBioActelion PharmaceuticalsCastle Creek PharmaceuticalsAvigenGene Therapy Research InstitutionOxford Glycobiology InstituteAmicus TherapeuticsAldagenRecursion Pharmaceuticals
Drugs Covered in Tay-Sachs Disease Pipeline Insight Market Research Report:AXO AAV GM2N-Acetyl-L-LeucineMiglustatCCP 010Lysosomal storage disease gene therapyResearch programme: Tay-Sachs disease gene therapyAcetylleucineResearch programme: calcium channel modulatorsCDP 923Research programme: Lysosomal storage disorder therapeuticsALD 601Research programme: rare genetic disorder therapeutics
r is categorized as a lysosomal storage disease. Tay-Sachs disease is broken down into the classic or infantile form, the juvenile form, and the adult or late-onset form. In individuals with infantile Tay-Sachs disease, symptoms typically first appear between three and five months of age. In individuals with the late-onset form, symptoms may become apparent anytime from adolescence through the mid-30s.
Companies Covered in Tay-Sachs Disease Pipeline Insight Market Research Report:
Axovant Gene Therapies
IntraBio
Actelion Pharmaceuticals
Castle Creek Pharmaceuticals
Avigen
Gene Therapy Research Institution
Oxford Glycobiology Institute
Amicus Therapeutics
Aldagen
Recursion Pharmaceuticals
Drugs Covered in Tay-Sachs Disease Pipeline Insight Market Research Report:
AXO AAV GM2
N-Acetyl-L-Leucine
Miglustat
CCP 010
Lysosomal storage disease gene therapy
Research programme: Tay-Sachs disease gene therapy
Acetylleucine
Research programme: calcium channel modulators
CDP 923
Research programme: Lysosomal storage disorder therapeutics
ALD 601
Research programme: rare genetic disorder therapeutics
Tay Sachs disease Pipeline Development Activities
The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Tay Sachs disease targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Tay Sachs disease pipeline report covers 6+ companies. Some of the key players include IntraBio Inc (IB1001-201), Castle Creek Pharmaceuticals (CCP 010) etc.
The report is built using data and information traced from the researchers proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.
Tay Sachs disease Analytical Perspective by Mart Research
In-depth Tay-Sachs Disease Commercial Assessment of products
This report provides an in-depth Commercial Assessment of therapeutic drugs have been included which comprises of collaborations, Licensing, Acquisition Deal Value Trends. The sub-segmentation is described in the report which includes Company-Company Collaborations (Licensing / Partnering), Company-Academia Collaborations, and Acquisition analysis in both Graphical and tabulated form.
Tay-Sachs Disease Clinical Assessment of products
The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.
To Buy Tay-Sachs Disease Pipeline Insight Market Research Report @ https://martresearch.com/paymentform/2/42159/Single_User
Scope of the report
The Tay Sachs disease report provides an overview of therapeutic pipeline activity for Tay Sachs disease across the complete product development cycle including all clinical and non-clinical stages
It comprises of detailed profiles of Tay Sachs disease therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details
Detailed Tay Sachs disease Research and Development progress and trial details, results wherever available, are also included in the pipeline study
Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type
Coverage of dormant and discontinued pipeline projects along with the reasons if available across Tay Sachs disease
Reasons to Buy
Establish a comprehensive understanding of the current pipeline scenario across Tay Sachs disease to formulate effective R&D strategies
Assess challenges and opportunities that influence Tay Sachs disease R&D
Develop strategic initiatives by understanding the focus areas of leading companies.
Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage. Get in detail information of each product with updated information on each project along with key milestones. Devise Tay Sachs disease in licensing and out licensing strategies by identifying prospective partners with progressing projects for Tay Sachs disease to enhance and expand business potential and scope. Our extensive domain knowledge on therapy areas support the clients in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs.
Table of Content for Tay-Sachs Disease Pipeline Insight Market Research Report:Chapter One: Report IntroductionChapter Two: Tay-Sachs Disease (GM2 gangliosidosis, type 1, HexA deficiency, Hexosaminidase A deficiency, Hexosaminidase alpha-subunit deficiency (variant B))Chapter Three: Tay-Sachs Disease Current Treatment PatternsChapter Four: Tay-Sachs Disease Mart Researchs Analytical PerspectiveChapter Five: Tay-Sachs Disease Pipeline TherapeuticsChapter Six: Tay-Sachs Disease -Products AnalysisChapter Seven: Recent TechnologiesChapter Eight: Tay-Sachs Disease Key CompaniesChapter Nine: Tay-Sachs Disease Key ProductsChapter Ten: Dormant and Discontinued ProductsChapter Eleven: Tay-Sachs Disease Unmet NeedsChapter Twelve: Tay-Sachs Disease Future Perspectives
List of Tables for Tay-Sachs Disease Pipeline Insight Market Research Report:Table 1. Diagnostic GuidelinesTable 2. Treatment GuidelinesTable 3. Assessment SummaryTable 4. Company-Company Collaborations (Licensing / Partnering) AnalysisTable 5. Tay-Sachs Disease Acquisition AnalysisTable 6. Assessment by Phase of DevelopmentTable 7. Assessment by Product Type (Mono / Combination)Table 8. Assessment by Stage and Product TypeTable 9. Assessment by Route of AdministrationTable 10. Assessment by Stage and Route of AdministrationTable 11. Assessment by Molecule TypeTable 12. Assessment by Stage and Molecule TypeTable 13. Assessment by MOATable 14. Assessment by Stage and MOATable 15. Late Stage Products (Phase-III)Table 16. Mid Stage Products (Phase-II)Table 17. Early Stage Products (Phase-I)Table 18. Pre-clinical and Discovery Stage ProductsTable 19. Inactive ProductsTable 20. Dormant ProductsTable 21. Discontinued Products
To Check Discount on Tay-Sachs Disease Pipeline Insight Market Research Report @ https://martresearch.com/contact/discount/2/42159
About us: Research is and will always be the key to success and growth for any industry. Most organizations invest a major chunk of their resources viz. time, money and manpower in research to achieve new breakthroughs in their businesses. The outcome might not always be as expected thereby arising the need for precise, factual and high-quality data backing your research. This is where MART RESEARCH steps in and caters its expertise in the domain of market research reports to industries across varied sectors.
Contact Us:
Mart Researchsales@martresearch.com+1-857-300-1122
Recommendation and review posted by Bethany Smith
CRISPR Therapeutics: At The Top Of My Shopping List – Seeking Alpha
CRISPR Therapeutics (CRSP) has been on my watchlist for a couple of years but the stars never aligned for me to pull the trigger on a buy. Due to some recent updates, I am moving CRSP up to the top of my year-end shopping list and will be stalking an entry point in the coming weeks or months.
I intend to discuss the primary reasons why I have waited for an entry, as well as what has tempted me to start a position. In addition, I discuss some of my leading downside risks associated with this ticker and how I plan to manage my potential position over the next year.
(Image Source: CRISPR)
CRISPR Therapeutics is a leader in gene editing, specifically in the advancement of Clustered Regularly Interspaced Short Palindromic Repeats-CRISPR-associated protein 9 "CRISPR-Cas9". CRISPR-Cas9 is a gene therapy, however, it is a revolutionary technology that intends to edit the deleterious gene. This is executed by altering explicit genomic sequences that should correct the bad gene or to alleviate the symptoms of the disease. Essentially, CRISPR is attempting to create curative gene therapies for both rare and common diseases.
CRISPR's programs can be divided up into ex vivo, where the company edits cells outside of the body and in vivo, the CRISPR-Cas9-based therapeutic targeted directly into the cells inside the body. CRISPR's leading pipeline programs take aim at hemoglobin related genetic disorders such as transfusion-dependent beta-thalassemia "TDT" and severe sickle cell disease "SCD". Both conditions desperately need a curative therapy because the current standard-of-care is insufficient. In addition to gene editing, the company has several gene-edited allogeneic cell therapy programs, including a few CAR-T candidates for hematological and solid tumor cancers. Furthermore, the company is taking gene-editing into regenerative medicines to address Type 1 diabetes, as well as taking on DMD and few other indications (Figure 1).
Figure 1: CRISPR Pipeline (Source: CRSP)
CRISPR-Cas9 for gene editing was co-invented by Dr. Emmanuelle Charpentier, who is one of CRISPR's founding members. The company now has the rights to Dr. Charpentier's CRISPR-Cas9 technologies, as well as some supplementary technology from other in-licensing efforts. What is more, CRISPR has a strong list of partnerships that will maximize CRISPR-Cas9's ability both clinically and commercially.
CRISPR has always been on my radar and I have admittedly traded the ticker a few times. However, I have been very cautious about investing in the company for a few reasons. One of which, is the fact that it is named after the technology associated with the gene therapies. Although there are other types of gene therapies, CRISPR appears to be the "brand" or term the market associates with all things gene therapy. Consequently, any bad news, setback, or regulatory failure in gene therapy has had a negative impact on the ticker. Essentially, CRISPR becomes a punching bag for anything that goes wrong in the industry. CRSP experienced strong selling pressure following Sarepta Therapeutics (SRPT) receiving a CRL for their DMD gene therapy. As a result, the stock fell from just under $50 a share to ~$43 per share in a few days. Of course, the rest of the industry experienced some selling pressure, but it appears CRSP gets the worst of it. As a result, I have been reluctant to commit to CRSP knowing that it will always be a target for shorts.
Another reason why I have passed on CRSP was due to its early pipeline. The company's pipeline is still mostly pre-clinical, so I would have been investing in science and not a mature product portfolio. Although I am happy to invest in an early-stage biotech/pharma company, I wanted to see if the FDA was willing to allow gene-editing therapies to be put into humans considering the controversy associated with the technology.
My last reason for holding off an investment was the valuation. The company's market valuation appeared to have a premium price on it. Admittedly, the company's high-priced valuation was due to its name and the hype around the gene therapy and not from a fundamental perspective. Although I am sold on the technology, I wasn't going to commit to a long-term investment to an early-stage company that is years away from a pivotal trial, regardless of the technology was from one of the co-founders of the CRISPR-Cas9.
In general, I knew the company was too early in the regulatory process and I expected the ticker to be toyed around with by traders and analysts. Therefore, I wanted to save myself from an unwanted rollercoaster ride of an investment.
The company is now a clinical-stage gene-editing company, which eliminates one of the reasons why I decided to hold off on starting a long-term investment. CRISPR's lead product candidate, CTX001, is ex-vivo CRISPR therapy that is being developed in collaboration with Vertex Pharmaceuticals (VRTX) for TDT or severe SCD. CTX001 is essentially a process that requires the company to engineer a patient's hematopoietic stem cells to increase the levels of fetal hemoglobin "HbF" in red blood cells.
Figure 2: CTX001 SCD (Source: CRSP)
The increase of HbF has the potential to assuage the need for transfusions for TDT and SCD patients.
Figure 3: CTX001 HbF (Source: CRSP)
CRISPR Therapeutics is enrolling in both Phase I/II studies of CTX001 in TDT and severe SCD. The company expects preliminary safety and efficacy data before the year-end. So far, the first TDT patient treated with CTX001 remains "transfusion independent, greater than four months following engraftment."
Now that CXT001 is in the clinic, we can expect several catalysts to come from these programs. Again, I did believe in the technology but the market needs to see that the pre-clinical data will transfer into humans. If the data is promising, we can expect an increase in attention from the market and from Street analysts. The company is expecting to report preliminary results for CTX001 by year-end, so I wouldn't mind having some skin-in-the-game ahead of that readout.
Another reason for a buy is the expanding use of the company's CRISPR-Cas9 technology. In addition to gene editing, the CRISPR-Cas9 has the potential to generate next-gen CAR-T therapies that may be superior to the contemporary autologous CAR-T (Figure 4).
Figure 4: CAR-T Highlights (Source: CRSP)
The company has programs including CTX110, a healthy donor-derived gene-edited allogeneic CAR-T therapy targeting CD19. In pre-clinical mouse studies, the company detected that CTX110 extended the survival in CD19-positive xenograft tumors. In addition to CTX110, the company has CTX120 that is targeting BCMA in multiple myeloma and CTX130 that could target both solid tumors and hematologic malignancies.
Figure 3: CTX110 & CTX120 (Source: CRSP)
In preclinical studies both CTX120 and CTX130 were able to record "complete tumor elimination" in their respective targets.
Figure 4: CTX130 (Source: CRSP)
In addition to cell-therapies, CRISPR is using their ex vivo gene-editing in regenerative medicine by using stem cells to restore or exchange damaged or malfunctioning tissue. Their leading regenerative program is diabetes with their partner, ViaCyte Inc (Figure 5).
Figure 5: In Diabetes (Source: CRSP)
CRISPR has other in vivo disease targets that impact the liver, lung and muscle. These will use the company's lipid nanoparticle-based delivery vehicles "LNPs" and AAV vectors to help deliver the genetic material.
Figure 6: Neuro & Liver (Source: CRSP)
Other notable programs include Glycogen Storage Disease Type Ia "GSDIa", DMD and cystic fibrosis.
Admittedly, I have always seen CRISPR as a pure gene-editing company, however, they have a diverse pipeline and the technology to expand it into numerous other indications and areas of therapy. I expect the company will expand on their research efforts, which should increase the pending value of the company and add some catalysts to the calendar.
The company intends to advance their CRISPR-Cas9 therapeutics both autonomously and in strategic partnerships (Figure 7). The company has closed three major partnerships with Vertex, Casebia/Bayer (OTCPK:BAYRY) and ViaCyte. These partnerships not only provide CRISPR with some support, but they confirm that other reputable companies see CRISPR as a leader in this field.
Figure 7: CRSP Partnerships (Source: CRSP)
As the company expands its pipeline, I anticipate an increase in the number of strategic partnerships and deals. In fact, the company recently announced a partnership with KSQ Therapeutics to in-license IP to advance their cell therapy programs.
My final reason for stalking an entry is the improved risk/reward scenario. The stock appears to have lost some momentum and has had a relatively flat 2019. The stock has recently experienced a strong pull-back, yet, the company has made substantial progress in both the pipeline and strategic collaborations.
Figure 8: CRSP Daily (Source: Trendspider)
This recent pull-back has cut the market cap down to ~$2B which I believe is fair considering the long-term outlook for the company.
Figure 9: CRSP Valuation (Source: Seeking Alpha)
Looking at the CRSP's annual revenue estimates (Figure 10), we can see the Street expects the company to have relatively flat revenues for the next couple of years and will start to experience strong revenue growth in the second half of the next decade. This rapid growth is expected to drop the forward price-to-sales ratio below 1x at some point in 2027. The sector's average price-to-sales is about 5x, so that would equal ~$13B market cap in 2027.
Figure 10: CRSP Annual Revenue Estimates (Source: Seeking Alpha)
I understand this is years away, but I expect these estimates to only improve as the company continues to add pipeline programs and other strategic partnerships. Indeed, I could wait another year or two to further reduce my risk and cost for time. However, I don't want to be left out of this ticker if the company starts reporting curative results in multiple programs. What would happen if the company demonstrates the potential to cure Type 1 diabetes? Do you think it will be trading at a $2B market cap? What about if they cure cystic fibrosis? Sickle Cell? Eliminate renal cancer with an autologous CAR-T therapy? I believe the company would be undervalued at $2B even if they only cured one of these indications. Assuming the company has at least one winner in their current pipeline, I have to say the current risk/reward is enticing enough for me to start a speculative position.
I believe the biggest threat to CRISPR comes from the impressive competition from other gene therapy companies and institutions. These include companies that are working on CRISPR-Cas9 technology such as Intellia Therapeutics (NTLA) and most notably Editas Medicine (EDIT). Other gene-editing companies such as bluebird bio (BLUE), Sangamo Therapeutics (SGMO), Cellectis (CLLS), Precision BioSciences (DTIL), and Allogene Therapeutics (ALLO) use other gene-editing platforms. There is a multitude of gene therapy companies that I didn't mention, but I think you get my point. Some of these companies are not in the same league as CRISPR, however, I believe CRISPR's biggest threat is something that is currently in a theoretical stage or perhaps hasn't been thought of yet. As gene therapy products begin to hit the market and start dethroning current standard-of-care therapies, I expect big pharma to start devoting a larger percentage of their R&D to gene therapies. As a result, more universities and institutions will start pioneering new CRISPR tech and perhaps another level of gene editing. If they are successful, they will most likely dethrone CRISPR-Cas9 as cutting-edge technology.
CRISPR is a developmental biotech company, so of course, the financials will be an issue until the company has a product on the market. At the end of Q2, the company had $427.9M in the bank. The company's R&D expenses were $39.5M for Q2, which led to a net loss of $53.7M. Usually, I would consider $428M to be a strong cash position for pre-revenue biotech, but I don't think we are seeing peak cash-burn. The company has several programs that haven't even hit the clinic yet, so we can expect that cash position to melt rapidly in the coming years. In fact, the company recently secured a $200M at-the-market sale of common stock, so we should expect the company to tap the market when they need to. Even then, investors need to accept the strong possibility the company will execute secondary offerings in the future.
CRISPR Therapeutics has evolved over the past couple of years and so has my view of a potential investment. The company's premium name brought a premium price, which generated a substantial amount of attention from traders who have created detached or arbitrary valuations for the ticker. Now, the company has moved into the clinic and will be generating data that could reveal curative level results for dreadful diseases and conditions. If CRISPR is able to gain regulatory approval, the product could replace the current standard-of-care for the indication and eventually dominate as patients demand a cure, rather than dealing with a lifetime of medications or procedures.
Due to this potential, I am moving CRSP up to the top of my shopping list as we close out 2019. I expect many of the speculative biotech names to experience end-of-the-year tax selling, so I am going to keep a close eye on the charts to see if I can get a nice discount to establish a large position. In the meantime, I rely on the chart's technicals to find an entry. Returning to figure 8, we can see the stock has returned to its previous trading range after a month of selling pressure. If the share price is able to hold this area over the next couple of weeks, I will look to click the buy button on a low volume day. If the stock breaks below $35, I will most likely hold off on a buy until the end of the year. Once I have established a position, I will look to add to my position following data readouts with a goal to have a full-sized position by the end of 2021.
Disclosure: I am/we are long SRPT. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Additional disclosure: I am also long BLUE.
Go here to read the rest:
CRISPR Therapeutics: At The Top Of My Shopping List - Seeking Alpha
Recommendation and review posted by Bethany Smith
CV Sciences, Inc. Appoints Dr. Paul Blake to its Board of Directors – GlobeNewswire
SAN DIEGO, Oct. 22, 2019 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the Company, CV Sciences, our, us or we), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced the appointment of Dr. Paul Blake to its Board of Directors effective October 21, 2019.
We are very pleased to have Dr. Blake join our Board of Directors, said Joseph Dowling, Chief Executive Officer of CV Sciences. His decades of experience leading pharmaceutical companies will be invaluable to us as we continue to strengthen our industry leadership position in CBD consumer products and drug development.
Dr. Blake brings with him deep expertise in clinical research, development, and medical affairs within the pharmaceutical industry. He currently serves as Chief Medical Officer at Heron Therapeutics Inc., a commercial-stage biotechnology company focused on improving the lives of patients suffering from pain or cancer by developing best-in-class treatments. At Heron, Dr. Blake is responsible for clinical research, medical affairs and drug safety.
Prior to joining Heron, he served as Chief Medical Officer of BioDelivery Sciences International, and before that he was the Chief Development Officer at Oxford BioMedica, a gene therapy company. His prior positions include Chief Medical Officer and Senior Vice President of Clinical Research and Development of Aeterna Zentaris, Inc., and Senior Vice President and then Executive Vice President of Worldwide Medical and Regulatory Operations at Cephalon, Inc. From 1992 to 1998, he held the position of Senior Vice President and Medical Director, Clinical Research and Development at SmithKline Beecham Pharmaceuticals (now GSK). Prior to that, he worked for ICI Pharmaceuticals (now Astra Zeneca) and G.D. Searle.
Dr. Blake is qualified in medicine from the Royal Free Hospital School of Medicine, London University. He is a Fellow of the Royal College of Physicians and a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians. He is also a Fellow of the American College of Clinical Pharmacology.
Dr. Blake has been involved in the development of several pharmaceutical drugs including: Tenormin, Zestril, Kytril, Relafen, Paxil, Coreg, Havrix, Hycamtin, Famvir, Requip, Avandia, Provigil and Fentora.
Dr. Blake served on the board of Memory Pharmaceutical, Inc., until it was purchased by Roche in 2009 and was a founding board member of Protez Pharmaceuticals, Inc., until it was purchased by Novartis in 2008. He was also a Director of ViaCell, Inc., until its purchase by Perkin Elmer in 2007 and of Oxford BioMedica from 2008 until 2016.
He has also served as a member of the Inter-Company Collaboration for AIDS Drug Development and as a trustee of the Childrens Health Fund.
I am excited to join CV Sciences Board of Directors and to contribute to the Companys mission of providing the highest-quality CBD products to consumers and patients, said Dr. Blake. CV Sciences is a leading pioneer in the CBD space and is uniquely positioned to continue to bring innovative products and novel therapeutics utilizing CBD to market.
About CV Sciences, Inc.
CV Sciences, Inc. (OTCQB:CVSI) operates two distinct business segments: a consumer product division focused on manufacturing, marketing and selling plant-based CBD products to a range of market sectors; and a drug development division focused on developing and commercializing CBD-based novel therapeutics utilizing CBD. The Companys PlusCBD Oil products are sold at more than 5,500 retail locations through the U.S. and it is the top-selling brand of hemp-derived CBD on the market, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry. CV Sciences state-of-the-art facility follows all guidelines for Good Manufacturing Practices (GMP) and the Companys full spectrum hemp extracts are processed, produced, and tested throughout the manufacturing process to confirm the cannabinoid content meets strict company standards. With a commitment to science, PlusCBD Oils benefits in healthy people are supported by human clinical research data, in addition to three published clinical case studies available on PubMed.gov. PlusCBD Oil was the first hemp CBD supplement brand to invest in the scientific evidence necessary to receive self-affirmed Generally Recognized as Safe (GRAS) status. CV Sciences, Inc. has primary offices and facilities in San Diego, California. Additional information is available from OTCMarkets.com or by visiting http://www.cvsciences.com.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.
CONTACT INFORMATION:Investor Contact:ICRScott Van Winkle617-956-6736scott.vanwinkle@icrinc.com
Media Contact:ICRCory Ziskind646-277-1232cory.ziskind@icrinc.com
Originally posted here:
CV Sciences, Inc. Appoints Dr. Paul Blake to its Board of Directors - GlobeNewswire
Recommendation and review posted by Bethany Smith
Gene Therapy Market 2019 Global Opportunity Analysis and Industry Forecast to 2025 – Honest Newsly
GlobalGene TherapyMarket,added byFior Marketsin its huge repository, offers a brilliant, complete research study of the globalGene Therapymarket. The report contains a detailed study of crucial market dynamics, including growth drivers, restraints, and opportunities. It chiefly focuses on current and historical market scenarios. It takes into account market competition, segmentation, geographical expansion, regional growth, market size, and other factors. The research study will surely benefit stakeholders, market players, investors, and other market participants. They will get a sound understanding of the global market and the industry.
Importantly, the report covers critical aspects of the competitive landscape and future changes in market competition. Market figures such as market share, revenue, production, consumption, gross margin, and price are accurately calculated. Additionally, the report has provided pricing analysis, industry chain analysis, product and application analysis, and other vital studies, giving a complete picture of the globalGene Therapymarket. The research is done by adopting a market method that contained both bottom-up and top-down approaches.
DOWNLOAD FREE SAMPLE REPORT:https://www.fiormarkets.com/report-detail/376052/request-sample
The various contributors involved in the value chain of the product include manufacturers, suppliers, distributors, intermediaries, and customers. The key manufacturers in this market include:Spark Therapeutics LLC, Bluebird Bio, UniQure N.V., Juno Therapeutics, GlaxoSmithKline, Chiesi Farmaceutici S.p.A., Bristol Myers Squibb, Celgene Corporation, Human Stem Cell Institute, Voyager Therapeutics, Shire Plc, Sangamo Biosciences, Dimension Therapeutics and others.
Geographically, this report is segmented into several key regions, from 2014 to2025(forecast), coveringNorth America,Europe,Asia-Pacific ,South America ,Middle East and Africa
Competition By The Company: Here, the competition in the worldwide market is analyzed, by price, revenue, sales, and market share by company, market rate, competitive situations landscape, and latest trends, merger, expansion, acquisition, and market shares of top companies.
What Market Factors Are Explained In The Report?
The market is segmented according to type, application, and region. A comprehensive explanation of the market assembling methodology, the use of advancement, conclusions of the world market players has been given. The segmentation study identifies leading segments and explains key factors supporting their growth in the global market. The report then sheds light on product positioning, customers perception of market competition, customer segmentation, consumer buying behavior, customer needs, and target customers.
BROWSE COMPLETE REPORT AND TABLE OF CONTENTS:https://www.fiormarkets.com/report/global-gene-therapy-market-by-type-germline-gene-376052.html
Key Questions Answered In The Market Report:-
Contact Us:Mark StoneSales ManagerPhone: (201) 465-4211Email:sales@fiormarkets.comWeb:www.fiormarkets.com
Taylor is the senior news reporter at Honest Newsly. He covers business and commodities news. Formerly, he worked with Western Mass News and Meredith COrporation as the senior news reporter.
See more here:
Gene Therapy Market 2019 Global Opportunity Analysis and Industry Forecast to 2025 - Honest Newsly
Recommendation and review posted by Bethany Smith
Fanconi Anemia (FA) Fanconi Hypoplastic Anemia Fanconi Hypoplastic Anemia Pipeline Insight Market Research Report 2019: by Trends, Development, Types,…
Fanconi Anemia (FA) Fanconi Hypoplastic Anemia Pipeline Insight Market Research 2019 report by Mart Research outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Fanconi Anemia (FA) Fanconi Hypoplastic Anemia pipeline landscape is provided which includes the disease overview and Fanconi Anemia (FA) Fanconi Hypoplastic Anemia treatment guidelines. The assessment part of the report embraces, in depth Fanconi Anemia (FA) Fanconi Hypoplastic Anemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Fanconi Anemia (FA) Fanconi Hypoplastic Anemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Fanconi Anemia Understanding
According to the Cancer and Blood Disorders Center, Fanconi Anemia (Fanconi hypoplastic anemia, Fanconi pancytopenia, Fanconi panmyelopathy) is a rare inherited disease characterized by multiple physical abnormalities, bone marrow failure, and a higher than normal risk of cancer. Researchers have shown that mutations in one of at least 15 different genes can cause FA. The proteins normally produced by these genes form a kind of cellular machine that helps detect and repair damaged DNA in blood stem cells and other cells in the body, in FA this damaged DNA repair is slowed. Therefore, blood stem cells (in the bone marrow) accumulate damaged DNA and do not survive. FA is usually discovered between birth and age 10-15 years; however, there also have been cases identified in adulthood. FA occurs equally in males and females. It has been identified in all ethnic groups. Researchers continue to clone and characterize the genes responsible for FA, which is bringing considerable progress in the diagnosis and understanding of this disease. It is more common in male as compared to female.
Fanconi Anemia Pipeline Development Activities
The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in FA targeted therapeutics development with respective active and dormant or discontinued projects. FA pipeline report covers 7+ companies. Some of the key players include Rocket pharma (RP-L102), Bellicum Pharmaceuticals (BPX-501), etc.
The report is built using data and information traced from the researchers proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.
Browse Full Fanconi Anemia (FA) Fanconi Hypoplastic Anemia Pipeline Insight Market Research Report @ https://martresearch.com/market-analysis/fanconi-anemia-(fa)-pipeline-insight/2/42145
Companies Covered in Fanconi Anemia (FA) Fanconi Hypoplastic Anemia Pipeline Insight Mart Research:Abeona TherapeuticsRocket PharmaceuticalsCIEMATCellenkosPluristem TherapeuticsBioLineRxForesee PharmaceuticalsGamida CellAmgenNovartis
Drugs Covered in Fanconi Anemia (FA) Fanconi Hypoplastic AnemiaPipeline Insight Market Research:Research programme: rare haematological disorder gene therapiesResearch programme: gene therapiesRP L101RP L102CK 0801PLX R18MotixafortideFP 045OmidubicelRomiplostimEltrombopag
Fanconi Anemia (FA) Fanconi Hypoplastic Anemia Analytical Perspective by Mart Research
In-depth Fanconi Anemia (FA) Fanconi Hypoplastic Anemia Commercial Assessment of products
This report provides an in-depth Commercial Assessment of therapeutic drugs have been included which comprises of collaborations, Licensing, Acquisition Deal Value Trends. The sub-segmentation is described in the report which includes Company-Company Collaborations (Licensing / Partnering), Company-Academia Collaborations, and Acquisition analysis in both Graphical and tabulated form.
Fanconi Anemia (FA) Fanconi Hypoplastic Anemia Clinical Assessment of products
The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.
Scope of the report
The Fanconi Anemia (FA) Fanconi Hypoplastic Anemia report provides an overview of therapeutic pipeline activity for Fanconi Anemia (FA) Fanconi Hypoplastic Anemia across the complete product development cycle including all clinical and non-clinical stages
It comprises of detailed profiles of Fanconi Anemia (FA) Fanconi Hypoplastic Anemia therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details
Detailed Fanconi Anemia (FA) Fanconi Hypoplastic Anemia Research and Development progress and trial details, results wherever available, are also included in the pipeline study
Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type
Coverage of dormant and discontinued pipeline projects along with the reasons if available across Fanconi Anemia (FA) Fanconi Hypoplastic Anemia.
To Buy Fanconi Anemia (FA) Fanconi Hypoplastic Anemia Pipeline Insight Market Research Report @ https://martresearch.com/paymentform/2/42145/Single_User
Reasons to Buy
Establish a comprehensive understanding of the current pipeline scenario across Fanconi Anemia (FA) Fanconi Hypoplastic Anemia to formulate effective R&D strategies
Assess challenges and opportunities that influence Fanconi Anemia (FA) Fanconi Hypoplastic Anemia R&D
Develop strategic initiatives by understanding the focus areas of leading companies.
Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
Get in detail information of each product with updated information on each project along with key milestones
Devise Fanconi Anemia (FA) Fanconi Hypoplastic Anemia in licensing and out licensing strategies by identifying prospective partners with progressing projects for Fanconi Anemia (FA) Fanconi Hypoplastic Anemia to enhance and expand business potential and scope
Our extensive domain knowledge on therapy areas support the clients in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs
Table of Content for Fanconi Anemia (FA) Fanconi Hypoplastic Anemia Pipeline Insight Market Research Report:Chapter One: Report IntroductionChapter Two: Fanconi Anemia (Fanconi hypoplastic anemia, Fanconi pancytopenia, Fanconi panmyelopathy)Chapter Three: Fanconi Anemia (FA) Fanconi Hypoplastic Anemia Current Treatment PatternsChapter Four: Fanconi Anemia (FA) Fanconi Hypoplastic Anemia Mart Researchs Analytical PerspectiveChapter Five: Fanconi Anemia (FA) Fanconi Hypoplastic Anemia Pipeline TherapeuticsChapter Six: Fanconi Anemia (FA) Fanconi Hypoplastic Anemia -Products AnalysisChapter Seven: Recent TechnologiesChapter Eight: Fanconi Anemia (FA) Fanconi Hypoplastic Anemia Key CompaniesChapter Nine: Fanconi Anemia (FA) Fanconi Hypoplastic Anemia Key ProductsChapter Ten: Dormant and Discontinued ProductsChapter Eleven: Fanconi Anemia (FA) Fanconi Hypoplastic Anemia Unmet NeedsChapter Twelve: Fanconi Anemia (FA) Fanconi Hypoplastic Anemia Future Perspectives
List of Tables for Fanconi Anemia (FA) Fanconi Hypoplastic Anemia Pipeline Insight Market Research Report:Table 1. Diagnostic GuidelinesTable 2. Treatment GuidelinesTable 3. Assessment SummaryTable 4. Company-Company Collaborations (Licensing / Partnering) AnalysisTable 5. Fanconi Anemia (FA) Fanconi Hypoplastic Anemia Acquisition AnalysisTable 6. Assessment by Phase of DevelopmentTable 7. Assessment by Product Type (Mono / Combination)Table 8. Assessment by Stage and Product TypeTable 9. Assessment by Route of AdministrationTable 10. Assessment by Stage and Route of AdministrationTable 11. Assessment by Molecule TypeTable 12. Assessment by Stage and Molecule TypeTable 13. Assessment by MOATable 14. Assessment by Stage and MOATable 15. Late Stage Products (Phase-III)Table 16. Mid Stage Products (Phase-II)Table 17. Early Stage Products (Phase-I)Table 18. Pre-clinical and Discovery Stage ProductsTable 19. Inactive ProductsTable 20. Dormant ProductsTable 21. Discontinued Products
To Check Discount on Fanconi Anemia (FA) Fanconi Hypoplastic Anemia Pipeline Insight Market Research Report @ https://martresearch.com/contact/discount/2/42145
Here is the original post:
Fanconi Anemia (FA) Fanconi Hypoplastic Anemia Fanconi Hypoplastic Anemia Pipeline Insight Market Research Report 2019: by Trends, Development, Types,...
Recommendation and review posted by Bethany Smith
Ichthyosis Pipeline Insight Market Research Report 2019: by Trends, Development, Types, Therapeutics, Drugs, Clinical Trials, Competitive Analysis…
Ichthyosis Pipeline Insight Market Research 2019 report by Mart Research outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Ichthyosis pipeline landscape is provided which includes the disease overview and Ichthyosis treatment guidelines. The assessment part of the report embraces, in depth Ichthyosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Ichthyosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Intrahepatic Cholangiocarcinoma Understanding
Ichthyosis, also known as disorders of keratinization (DOK), encompass a heterogeneous group of skin diseases linked by the common finding of abnormal barrier function, which initiates a default compensatory pathway of hyperproliferation. The unifying phenotypic feature of the ichthyosis is the clinical manifestation of localized and/or generalized scaling. Other include erythroderma, palmoplantar keratoderma, hypohidrosis, and recurrent infections. Most known forms of ichthyosis are a rare genetic disorder, which are hereditary in nature (some forms are dominant and some are recessive). Although ichthyoses are primarily inherited disorders with onset at or shortly after birth, rare acquired forms have been reported in the setting of malignancy, nutritional deficiency, and autoimmune or infectious disease. Mutations in over 50 genes have been reported to cause ichthyoses and these affect a host of cellular functions including DNA repair, lipid biosynthesis, adhesion, and desquamation as well as other pathways. Ichthyosis vulgaris (IV) and X-linked recessive ichthyosis (XLRI) are classified as the common ichthyoses, given their high prevalence.
Ichthyosis Pipeline Development Activities
The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Ichthyosis targeted therapeutics development with respective active and dormant or discontinued projects Ichthyosis pipeline report covers 11+ companies. Some of the key players include Mayne Pharma/Galderma (Trifarotene), Patagonia Pharmaceuticals (PAT-001), Exicure (XCUR 17), etc.
The report is built using data and information traced from the researchers proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.
Ichthyosis Analytical Perspective by Mart Research
In-depth Ichthyosis Commercial Assessment of products
This report provides an in-depth Commercial Assessment of therapeutic drugs have been included which comprises of collaborations, Licensing, Acquisition Deal Value Trends. The sub-segmentation is described in the report which includes Company-Company Collaborations (Licensing / Partnering), Company-Academia Collaborations, and Acquisition analysis in both Graphical and tabulated form.
Ichthyosis Clinical Assessment of products
The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.
Browse Full Ichthyosis Pipeline Insight Market Research Report @ https://martresearch.com/market-analysis/ichthyosis-pipeline-insight/2/42147
Companies Covered in Ichthyosis Pipeline Insight Mart Research:Patagonia PharmaceuticalsCellegy PharmaceuticalsMayne Pharma/GaldermaJanssen PharmaceuticaFoamixDermaXonAldeyra TherapeuticsAzitraBristol-Myers SquibbAllerganChugai PharmaceuticalKrystal BiotechGlaxoSmithKlineNovartisTeijin PharmaExicure
Drugs Covered in IchthyosisPipeline Insight Market Research:IsotretinoinMonolaurinTrifaroteneLiarozoleAmmonium lactateDX 0386ReproxalapDX 0308Research programme: skin disorder therapeuticsAcitretinAmmonium lactate; BMS-186091MaxacalcitolBercolagene telserpavecResearch programme: gene therapies; KB 105BMS 181163SecukinumabTacalcitolResearch programme: SNA based therapeuticsXCUR 17DX 0332
Ichthyosis Analytical Perspective by Mart Research
In-depth Ichthyosis Commercial Assessment of products
This report provides an in-depth Commercial Assessment of therapeutic drugs have been included which comprises of collaborations, Licensing, Acquisition Deal Value Trends. The sub-segmentation is described in the report which includes Company-Company Collaborations (Licensing / Partnering), Company-Academia Collaborations, and Acquisition analysis in both Graphical and tabulated form.
Ichthyosis Clinical Assessment of products
The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.
Scope of the report
The Ichthyosis report provides an overview of therapeutic pipeline activity for Ichthyosis across the complete product development cycle including all clinical and non-clinical stages
It comprises of detailed profiles of Ichthyosis therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details
Detailed Ichthyosis Research and Development progress and trial details, results wherever available, are also included in the pipeline study
Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type
Coverage of dormant and discontinued pipeline projects along with the reasons if available across Ichthyosis.
To Buy Ichthyosis Pipeline Insight Market Research Report @ https://martresearch.com/paymentform/2/42147/Single_User
Reasons to Buy
Establish a comprehensive understanding of the current pipeline scenario across Ichthyosis to formulate effective R&D strategies
Assess challenges and opportunities that influence Ichthyosis R&D
Develop strategic initiatives by understanding the focus areas of leading companies.
Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
Get in detail information of each product with updated information on each project along with key milestones
Devise Ichthyosis in licensing and out licensing strategies by identifying prospective partners with progressing projects for Ichthyosis to enhance and expand business potential and scope
Our extensive domain knowledge on therapy areas support the clients in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs
Table of Content for Ichthyosis Pipeline Insight Market Research Report:Chapter One: Report IntroductionChapter Two: IchthyosisChapter Three: Ichthyosis Current Treatment PatternsChapter Four: Ichthyosis Mart Researchs Analytical PerspectiveChapter Five: Ichthyosis Pipeline TherapeuticsChapter Six: Ichthyosis -Products AnalysisChapter Seven: Recent TechnologiesChapter Eight: Ichthyosis Key CompaniesChapter Nine: Ichthyosis Key ProductsChapter Ten: Dormant and Discontinued ProductsChapter Eleven: Ichthyosis Unmet NeedsChapter Twelve: Ichthyosis Future Perspectives
List of Tables for Ichthyosis Pipeline Insight Market Research Report:Table 1. Diagnostic GuidelinesTable 2. Treatment GuidelinesTable 3. Assessment SummaryTable 4. Company-Company Collaborations (Licensing / Partnering) AnalysisTable 5. Ichthyosis Acquisition AnalysisTable 6. Assessment by Phase of DevelopmentTable 7. Assessment by Product Type (Mono / Combination)Table 8. Assessment by Stage and Product TypeTable 9. Assessment by Route of AdministrationTable 10. Assessment by Stage and Route of AdministrationTable 11. Assessment by Molecule TypeTable 12. Assessment by Stage and Molecule TypeTable 13. Assessment by MOATable 14. Assessment by Stage and MOATable 15. Late Stage Products (Phase-III)Table 16. Mid Stage Products (Phase-II)Table 17. Early Stage Products (Phase-I)Table 18. Pre-clinical and Discovery Stage ProductsTable 19. Inactive ProductsTable 20. Dormant ProductsTable 21. Discontinued Products
To Check Discount on Ichthyosis Pipeline Insight Market Research Report @ https://martresearch.com/contact/discount/2/42147
About us: Research is and will always be the key to success and growth for any industry. Most organizations invest a major chunk of their resources viz. time, money and manpower in research to achieve new breakthroughs in their businesses. The outcome might not always be as expected thereby arising the need for precise, factual and high-quality data backing your research. This is where MART RESEARCH steps in and caters its expertise in the domain of market research reports to industries across varied sectors.
Contact Us:
Mart Researchsales@martresearch.com+1-857-300-1122
Go here to read the rest:
Ichthyosis Pipeline Insight Market Research Report 2019: by Trends, Development, Types, Therapeutics, Drugs, Clinical Trials, Competitive Analysis...
Recommendation and review posted by Bethany Smith
Vamorolone Designated Promising Innovative Medicine (PIM) for Treatment of Duchenne Muscular Dystrophy by the UK MHRA – BioSpace
Pratteln, Switzerland, October 21, 2019 Santhera Pharmaceuticals (SIX: SANN) announces that the UKs Medicines and Healthcare Products Regulatory Agency (MHRA) has informed ReveraGen BioPharma about having designated vamorolone as Promising Innovative Medicine (PIM) for the treatment of Duchenne muscular dystrophy (DMD).
We congratulate ReveraGen on this success and are excited about the PIM designation as it further validates the potential of vamorolone as an innovative treatment approach addressing the high unmet medical need in young patients with DMD, said Thomas Meier, PhD, CEO of Santhera.
The PIM designation indicates that the UK MHRA considers vamorolone a promising candidate for the Early Access to Medicines Scheme (EAMS). In the UK, the EAMS, of which PIM is the first step, aims to give patients with life threatening or seriously debilitating conditions access to medicines that do not yet have a marketing authorization when there is a clear unmet medical need.
Vamorolone is a first-in-class steroidal anti-inflammatory investigational drug in development as treatment for DMD. Data from non-clinical and clinical studies indicated that vamorolone treatment results in a persistent improvement of muscle function with less adverse effects typically reported for traditional corticosteroids [1-6].
Vamorolone has been granted Orphan Drug status in the US and in Europe and has received Fast Track and Rare Pediatric Disease designations by the US FDA.
About Vamorolone first-in-class dissociative steroid
Vamorolone is a first-in-class drug candidate that binds to the same receptors as corticosteroids but modifies the downstream activity of the receptors. This has the potential to dissociate efficacy from typical steroid safety concerns and therefore could replace existing corticosteroids, the current standard of care in children and adolescent patients with DMD. There is significant unmet medical need in this patient group as high dose corticosteroids have severe systemic side effects that detract from treatment compliance and patient quality of life.
The currently ongoing 48-week Phase IIb VISION-DMD study (VBP15-004; NCT03439670) is designed as a pivotal trial to demonstrate efficacy and safety of vamorolone compared with prednisone and placebo in 120 boys aged 4 to <7 with DMD that have not yet been treated with corticosteroids. For more information: https://vision-dmd.info/2b-trial-information.
Vamorolone is being developed by US-based ReveraGen BioPharma Inc. with participation in funding and design of studies by several international non-profit foundations, the US National Institutes of Health, the US Department of Defense and the European Commissions Horizon 2020 program. In November 2018, Santhera acquired from Idorsia the option to an exclusive sub-license to vamorolone in all indications and all countries worldwide (except Japan and South Korea).
About Santhera
Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular and pulmonary diseases with high unmet medical need. Santhera is building a Duchenne muscular dystrophy (DMD) product portfolio to treat patients irrespective of causative mutations, disease stage or age. A marketing authorization application for Puldysa (idebenone) is currently under review by the European Medicines Agency. Santhera has an option to license vamorolone, a first-in-class dissociative steroid currently investigated in a pivotal study in patients with DMD to replace standard corticosteroids. The clinical stage pipeline also includes POL6014 to treat cystic fibrosis (CF) and other neutrophilic pulmonary diseases, as well as omigapil and an exploratory gene therapy approach targeting congenital muscular dystrophies. Santhera out-licensed ex-North American rights to its first approved product, Raxone (idebenone), for the treatment of Leber's hereditary optic neuropathy (LHON) to Chiesi Group. For further information, please visit http://www.santhera.com.
Raxone and Puldysa are trademarks of Santhera Pharmaceuticals.
About ReveraGen BioPharma
ReveraGen was founded in 2008 to develop first-in-class dissociative steroidal drugs for Duchenne muscular dystrophy and other chronic inflammatory disorders. The development of ReveraGens lead compound, vamorolone, has been supported through partnerships with foundations worldwide, including Muscular Dystrophy Association USA, Parent Project Muscular Dystrophy, Foundation to Eradicate Duchenne, Save Our Sons, JoiningJack, Action Duchenne, CureDuchenne, Ryans Quest, Alexs Wish, DuchenneUK, Pietros Fight, Michaels Cause, and Duchenne Research Fund. ReveraGen has also received generous support from the US Department of Defense CDMRP, National Institutes of Health (NCATS, NINDS, NIAMS), and European Commission (Horizons 2020). http://www.reveragen.com
References:
[1] Hoffman EP et al. (2019). Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function. Neurology 93(13):e1312-e1323. doi:10.1212/WNL.0000000000008168
[2] Hoffman EP et al. (2018). Phase 1 trial of vamorolone, a first-in-class steroid, shows improvements in side effects via biomarkers bridged to clinical outcomes. Steroids 134: 43-52.
[3] Conklin LS et al. (2018). Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug. Pharmacol Res. 136:140-150. doi: 10.1016/j.phrs.2018.09.007.
[4] Mavroudis PD et al. (2019). Population pharmacokinetics of vamorolone (VBP15) in healthy men and boys with Duchenne muscular dystrophy. J Clin Pharmacol. 59(7):979-988. doi: 10.1002/jcph.1388.
[5] Heier CR at al. (2013). VBP15, a novel antiinflammatory and membranestabilizer, improves muscular dystrophy without side effects. EMBO Mol Med 5: 15691585
[6] Heier CR et al. (2019). Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy. Life Science Alliance DOI 10.26508/lsa.201800186
For further information please contact:
Santhera
public-relations@santhera.com or
Eva Kalias, Head External Communications
Phone: +41 79 875 27 80
ReveraGen
Eric Hoffman, PhD, CEO
Phone: +1 240-672-0295
Disclaimer / Forward-looking statements
This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.
# # #
The rest is here:
Vamorolone Designated Promising Innovative Medicine (PIM) for Treatment of Duchenne Muscular Dystrophy by the UK MHRA - BioSpace
Recommendation and review posted by Bethany Smith
Cancer Gene Therapy Market Size, Market Opportunities, SWOT Analysis, Key Players and Forecast to 2024 – The Charterian
Cancer Gene Therapy Market Report 2019 to 2024 is the definitive study of the global Cancer Gene Therapy market. The content includes orientation technology, industry drivers, geographic trends, market statistics, market forecasts, producers, and equipment suppliers.
The report firstly introduced the Cancer Gene Therapy basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the worlds main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. In the end, the report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.
About Cancer Gene Therapy Industry
Analyst projects that the Cancer Gene Therapy market size will grow from XX Million USD in 2018 to XX Million USD by 2024, at an estimated CAGR of XX%. The base year considered for the study is 2018, and the market size is projected from 2019 to 2024.
Look insights of Global Cancer Gene Therapyindustry market research report athttps://www.pioneerreports.com/report/411426
The overviews, SWOT analysis and strategies of each vendor in the Cancer Gene Therapy market provide understanding about the market forces and how those can be exploited to create future opportunities.
Key Players in this Cancer Gene Therapy market are:
By TypeGene Induced Immunotherapy, Oncolytic Virotherapy, Gene Transfer
By ApplicationHospitals, Diagnostics Centers, Research Institutes
By
By
By
By
This is the one market research report to help you make the right strategic decisions.
Request sample report to see for yourself athttps://www.pioneerreports.com/request-sample/411426
This research report consists of the worlds crucial region market share, size (volume), trends including the product profit, price, Value, production, capacity, capability utilization, supply, and demand and industry growth rate.
Important application areas of Cancer Gene Therapy are also assessed on the basis of their performance. Market predictions along with the statistical nuances presented in the report render an insightful view of the Cancer Gene Therapy market. The market study on Global Cancer Gene Therapy Market 2018 report studies present as well as future aspects of the Cancer Gene Therapy Market primarily based upon factors on which the companies participate in the market growth, key trends and segmentation analysis.
Geographically this report covers all the major manufacturers from India, China, USA, UK, and Japan. The present, past and forecast overview of Cancer Gene Therapy market is represented in this report.
Look into Table of Content of Cancer Gene Therapy Market Report at https://www.pioneerreports.com/TOC/411426
The Cancer Gene Therapy Market Report is Prepared with the Main Agenda to Cover the following points:
Report Price: USD 3500
No of Pages in Cancer Gene Therapy Market:NOP
Analysis & Forecast Time Period: 2015-2024
Purchase Reportathttps://www.pioneerreports.com/checkout/411426
See the original post here:
Cancer Gene Therapy Market Size, Market Opportunities, SWOT Analysis, Key Players and Forecast to 2024 - The Charterian
Recommendation and review posted by Bethany Smith
Is a Treatment for CMT in the Works? – Charcot-Marie-Tooth News
I burned my finger the other day. I didnt feel it right away, which is not that odd of an occurrence for me.
Often, I dont feel the heat and dont realize I have burned myself while cooking. I have Charcot-Marie-Tooth (CMT) type 1A, which may affect the feeling in my extremities.
CMT is also known as hereditary motor sensory neuropathy or peroneal muscular atrophy. Faulty genes may damage nerve cells or interfere with the formation of myelin, an insulating material that protects electrical signals as they travel through the bodys nervous system, including to the arms and legs.
When the myelin sheath is damaged, nerve impulses can slow or stop. That may explain why it can take 30 seconds for me to feel pain after stubbing my toe or burning myself. It would be nice if there was a way to stop that effect of CMT.
There is ongoing research on ways to treat CMT. One recent study claimed that varying amounts of lecithin seemed to ease the course of the disease, but this has not been tested on humans.
Pharnext is sponsoring clinical trials for PXT3003, a combination of baclofen, naltrexone, and sorbitol. According to the manufacturer, PXT3003 has shown positive effects on muscle cells, neuromuscular junctions, and immune cells. In current studies, the investigational medications long-term safety is being researched. Meanwhile, earlier this year, the U.S. Food and Drug Administration granted fast track designation for PXT3003s development.
This is an exciting time for CMT1A patients. The research is promising. In preclinical trials, PXT3003 inhibited the overexpression of the PMP22 gene and eased neuromuscular symptoms. In clinical trials, patients showed improvements. The amount of research and the positive results give us hope that a treatment may be on the horizon.
For now, only mobility aids, physical therapy, and medication can help ease the pain. These help us manage everyday living, but dont target the cause of the disease.
I am excited to see where the research leads. My hope is that these treatments are found to be effective and can help those of us with CMT1A. I would be happy to have medication available that stops the progression of my symptoms. It would be even better if the effects could be reversed, but I know that is asking a lot.
I would settle for not burning my fingertips when cooking.
***
Note: Charcot-Marie-Tooth News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The opinions expressed in this column are not those of Charcot-Marie-Tooth News or its parent company, BioNews Services, and are intended to spark discussion about issues pertaining to Charcot-Marie-Tooth.
Jill Price is a fourth grade teacher and a mom to a teenage son. She was diagnosed with CMT 1a at the age of 2. Jill loves to travel and enjoys spending time with her family and friends.
View post:
Is a Treatment for CMT in the Works? - Charcot-Marie-Tooth News
Recommendation and review posted by Bethany Smith
The global predictive genetic testing & consumer/wellness genomics market size is expected to reach USD 8.5 billion by 2025, registering a CAGR of…
NEW YORK, Oct. 21, 2019 /PRNewswire/ --
Predictive Genetic Testing & Consumer/Wellness Genomics Market Size, Share & Trends Analysis Report By Test Type (Population Screening, Susceptibility), By Application, By Setting Type, And Segment Forecasts, 2019 - 2025
Read the full report: https://www.reportlinker.com/p05807251/?utm_source=PRN
The global predictive genetic testing & consumer/wellness genomics market size is expected to reach USD 8.5 billion by 2025, registering a CAGR of 13.9% over the forecast period. Factors influencing the market progression include growing awareness about utilization of genetic tests that aid in prediction of gene susceptibility to disease development prior to symptoms. Moreover, rise in sales of these products owing to growing inclination of physicians is driving the market.
Introduction of novel platforms in next-generation sequencing technology aids in enhancing the accuracy of predictive genetic and consumer genomics kits. Market participants are engaged in implementing novel protocols to launch products that require minimal technical assistance and provide optimal customer satisfaction.
Pharmaceutical firms are engaged in several agreement models with genomic vendors for the release of novel therapeutics based on patient's phenotypic and genotypic information. For instance, in July 2018, GlaxoSmithKline plc purchased 23andMe's customer data to develop a new drug, thus promoting patient-centered healthcare.
Further key findings from the study suggest: High adoption rate of these products in clinical practice for detection of disease susceptibility resulted in the largest share of this segment in 2018 Growing awareness related to direct to consumer (DTC) genetic tests and entry of new players is attributive to the fastest growth of the consumer genomics segment Genetic susceptibility tests are of great interest in gynecology and endocrinology-related research and diagnosis, thus allowing it to capture the maximum revenue share. These tests enable the identification of susceptible genes or mutations in adenomyosis, endometriosis, and postmenopausal osteoporosis Application of predictive genetic and consumer genomics is highest in the detection of breast and ovarian cancer as these tests hold the potential to identify BRCA mutations in patients Advent of predictive tests for identification of MLH1, MSH2 genes for colorectal cancer diagnosis is expected to fuel market growth in the coming years Colorectal screening initiatives such as mass screening and population-based screening are expected to boost segment growth North America dominated the market with the largest revenue share in 2018 owing to the presence of major players and high adoption rate Asia Pacific is expected to witness substantial growth in the coming years owing to increasing adoption of these products in developing economies Manufacturers contributing significantly to market growth include Pathway Genomics; ARUP Laboratories; BGI; Illumina, Inc.; 23andMe, Inc.; Color Genomics Inc.; and Myriad Genetics, Inc. Established as well as emerging companies are involved in adopting strategic moves for the launch of novel products.
Read the full report: https://www.reportlinker.com/p05807251/?utm_source=PRN
About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001
SOURCE Reportlinker
Recommendation and review posted by Bethany Smith
Ochsner Health System teaming up with Color on population health pilot – FierceHealthcare
Louisiana-based Ochsner Health System is partnering with Color to launch a population health pilot program, tyinggenetic information into preventive care.
Calling it the first "fully-digital population health program," Ochsner will work with the health technology company to incorporateclinical genomics into primarycare with a focuson impacting patients' health further downstream.
Developed by Ochsners innovation lab, innovationOchsner (iO), the health systems program willidentify patients who are at higher risk for certain hereditary cancers and heart disease so these diseases can be detected early or prevented.
Like this story? Subscribe to FierceHealthcare!
The healthcare sector remains in flux as policy, regulation, technology and trends shape the market. FierceHealthcare subscribers rely on our suite of newsletters as their must-read source for the latest news, analysis and data impacting their world. Sign up today to get healthcare news and updates delivered to your inbox and read on the go.
This marks another big partnership for Color this year. The company inked a similar collaboration with Chicago-based NorthShore University HealthSystem, called DNA10K, that will provide more than10,000 NorthShore patients access to Colors clinical-grade genetic testing and whole genome sequencing.Atthe time, it was touted as the largest primary care genomics program in the U.S.
RELATED:Mount Sinai to launch $100M center dedicated to AI, precision medicine
Physician practices are beginning to incorporate genomics into primary care as well.Murfreesboro Medical Clinic and SurgiCenter in Tennessee are working with technology company2bPrecise, a subsidiary of health IT company Allscripts, to integrate pharmacogenomic testresults at the point of care.
In August, Color was awarded a $4.6 million grant by the National Institutes of Health to serve as the nationwide genetic counseling service for its All of Us Research Program.
With this pilot program, Ochsner is focused on screening patients with genetic mutations that put them at increased risk for three conditionshereditary breast and ovarian cancer syndrome due to genetic mutations in the BRCA1 and BRCA2 genes; Lynch syndrome,associated with increased risk in colorectal, endometrial, ovarian and other cancers; and familial hypercholesterolemia (FH), which increases the risk for heart disease or stroke.
The Centers for Disease Control and Prevention reports thatnearly 2 million people in the U.S. are at increased risk for adverse health outcomes because they have genetic mutations with one of thosethree conditions.
Genetic screening can make a meaningful difference to patients through early detection and screening. Most consumers have access to home genetic screening tests but may not have the tools, resources, and collaboration needed to take action should they receive questionable results, said Richard Milani, M.D., chief clinical transformation officer for the Ochsner Health System and medical director for iO.
RELATED:How a Nashville-area clinic teamed up with Allscripts on precision medicine
Ochsner provides patient care across40 owned, managed and affiliated hospitals and specialty hospitals and more than 100 health centers and urgent care centers.The partnership will combine Colors capabilities inmedical-grade genetics, clinical services and patient engagement and the health system's experience withpersonalized medicineand integrating it into routine patient care, the organizations said in a press release.
As part of the program, selected patients will be enrolled into the program digitally and will receive access to genetic testing and counseling.Genetic testing results will bestored in the patients Epic electronic health record so patients and providers have access to the genetic information.
RELATED:UCLA Health deploys Microsoft Azure to accelerate medical research, precision medicine at the point of care
Ochsner also has developed clinical decision support tools and a robust provider education program for both primary care and specialty providers to integrate into clinical practice.
New technology tools like clinical genomics will enableOchsner physicians to better understand individualized risk among its patient population and create action plans that can detect or prevent disease, according to the health system.
We know there are many factors that influence health, and genetic insights provide an additional data point to allow us to develop and deliver a more personalized approach in partnership with our patients," Milani said.
"Integrating this information into the patients electronic health record so doctors can review the results and discuss proactive treatment recommendations is yet another example of how we are reengineering care, informing smarter decisions by healthcare providers and empowering patients to become more involved in their health," he said.
Read more:
Ochsner Health System teaming up with Color on population health pilot - FierceHealthcare
Recommendation and review posted by Bethany Smith
LyGenesis Closes $4 Million Convertible Debt Financing to Begin Clinical Development of its Liver Regeneration Technology – PRNewswire
PITTSBURGH, Oct. 21, 2019 /PRNewswire/ -- LyGenesis, Inc., a biotechnology company focused on organ regeneration, announced today that they have completed a total of $4 million in private financing of convertible notes from Juvenescence, Ltd. and Longevity Vision Fund. Their technology uses lymph nodes as bioreactors to regrow functioning organs within a patient's own body. This financing will enable LyGenesis's lead program in liver regeneration to transition into clinical development, beginning with a Phase 2a clinical trial for patients with end stage liver disease in 2020.
"We have advanced our liver regeneration program through preclinical trials and this financing will help us to rapidly transition into a clinical-stage biotechnology company," said Michael Hufford, PhD, Co-Founder and CEO of LyGenesis. "Our ability to use the lymph node as a bioreactor for organogenesis is also generating interest from partner companies looking for an enabling technology so that their genetically modified cell therapies are able to engraft, proliferate, vascularize, and produce a therapeutic effect in patients."
"We are thrilled to continue our financial support of LyGenesis as they transition into clinical development," said Greg Bailey, MD, Co-Founder and CEO of Juvenescence, and a member of LyGenesis's Board of Directors. Sergey Young, founder of Longevity Vision Fund, said "The ability to regenerate functioning ectopic organs was science fiction just a few short years ago. The progress of LyGenesis's technology is emblematic of the rapid advances we are witnessing as biotechnology transitions from bench research, to preclinical models, and now into the clinic."
About LyGenesis, Inc.LyGenesis is a biotechnology company with an organ regeneration technology platform enabling a patient's lymph nodes to be used as bioreactors to regrow functioning ectopic organs. LyGenesis's lead allogeneic cell therapy program is focused on liver regeneration for patients with end stage liver disease. Its drug development pipeline includes thymus, pancreas, and kidney regeneration. Privately held, LyGenesis is headquartered in Pittsburgh, Pennsylvania. To learn more, please visit lygenesis.com.
About Juvenescence, Ltd.Juvenescence Limited is a life sciences company developing therapies to increase healthy human longevity. It was founded by Jim Mellon, Dr. Greg Bailey and Dr. Declan Doogan. The Juvenescence team are highly experienced drug developers, entrepreneurs and investors with a significant history of success in the life sciences sector. Juvenescence will create, partner with or invest in new companies with longevity-related therapeutics, by in-licensing compounds from academia and industry, or forming joint ventures to develop therapeutics for longevity. Juvenescence believes that recent advances in science have greatly improved our understanding of the biology of aging and seeks to develop therapeutics with the possibility of slowing, halting or potentially reversing elements of aging. To learn more, please visit juvenescence.ltd.
About Longevity Vision FundLongevity Vision Fundis a $100M life extension-focused investment fund dedicated to making longevity affordable and accessible to all. Founded by Sergey Young, the fund accelerates breakthroughs in longevity by investing in start-ups and companies that develop technologies, products, and services that extend human lifespans and overcome the negative effects of aging. The Fund provides funding to biotech and life extension-focused companies developing early diagnostics, AI in healthcare, and therapies addressing age-related diseases. To learn more, please visit lvf.vc.
Media Contact:Michael Hufford, PhD+1.858.603.2514226496@email4pr.com
SOURCE LyGenesis, Inc.
Recommendation and review posted by Bethany Smith
Power Analytics Expands Global Patent Portfolio and the new release of software version 6.2 for DesignBase – Yahoo Finance
RALEIGH, N.C., Oct. 21, 2019 (GLOBE NEWSWIRE) -- Power Analytics, a Global corporation, and its majority shareholder Wavetech Global, Inc (the "Company" or "Power"), a global next generation technology platform company that specializes in critical system monitoring, prediction, simulation and data-analytics announced today a significant expansion of its global patent portfolio, with the granting of a new patent, demonstrating its ongoing commitment to innovation and leadership in the emerging global digital twin software industry. In addition, Power Analytics is excited to announce a new release of the Companys leading analytical software DesignBase 6.2, the core of the Companys real time microgrid and data-center product offerings including the Power Digital Twin. This release expands key areas of innovation in energy storage, time-series and dynamic analytical capability along with asset management and asset optimization.
The companys U.S. and international patent portfolio now totals 25 issued patents, with a new patent expanding coverage of real-time microgrid power management systems (SYSTEMS AND METHODS FOR REAL-TIME DC MICROGRID POWER ANALYTICS FOR MISSION-CRITICAL POWER SYSTEMS). Power Analytics patents include sophisticated real-time modeling and simulations technology, architecture, engineering and applied sciences to help its customers and partners protect their network infrastructure by preventing network downtime and allowing them to run their operations more efficiently.
From the beginning, we recognized the importance of developing and then protecting our technology, said Kevin Meagher, Power Analytics President. As a pioneer in the Power Digital Twin software, we know via our priority data capture and modeling software that we were and are ahead of the power simulation ecosystem. To have our creativity recognized by patent offices around the globe (United States, Canada, Europe, Japan, Australia and others) is a source of pride for the entire Power Analytics team and should be very comforting to our Customers, Partners and Investors.
Power Analytics leverages over 30,000 different libraries (grid element library) of devices and collecting in real-time while analyzing and running a predictive simulation of each device to improve operational efficiency rates and eliminate downtime cost impacts. The Company continues to innovate to meet the challenges that customers have in navigating the complex and dynamic network infrastructure management ecosystem. With more than 25 patent applications, Power Analytics Network Gatewayplatforms address the current marketplace requirements and Future Proof Customers ongoing infrastructure management needs.
Our proprietary technology enables us to monitor, model, predict and protect in real-time millions of Power and Network Identification Components (PICs & NICs), and give distinct insight into how to improve efficiency and improve reliability. Our platform and models can consume and process hundreds of thousands of datapoints per second and do so for some of the most important networks in the world. Our goal is to use maintain our innovation lead further invention that make power, internet and mobile network infrastructure more reliable, cost efficient and secure., stated Michael Kotlarz, Power Analytics is always looking forward to what is coming next and is furiously innovating for the challenges our Customers are facing today and likely will face in the future. Seeing patent authorities worldwide continue to point to Power Analytics pioneering technology as unique and applicable innovations is very rewarding.
Keith Barksdale of Power Analytics Global and BV Advisory Partners stated, We are excited to expand our IP portfolio and the release of a newer version of our Digital Twin software. In the coming months we will accelerate the launch of more of our proprietary AI based software product offerings that will help our customers and partners realize greater cost savings, increased revenue opportunities, and better operational efficiencies from their critical network infrastructure.
About Power Analytics GlobalPower Analytics Global is a global next generation energy management company that specializes in asset lifecycle extension, intellectual property development, and real-time analytics and asset management for power and industries supported by power. The Company offers a global portfolio of end-to-end energy optimization and lifecycle management solutions developed from proprietary intellectual property, engineered systems, and operational expertise. Power Analytics extensive suite of products include power asset life extension, operational servicing and automation, lifetime cost reduction, and real-time heterogeneous power source switching. Additional information regarding Power Analytics may be found on Power Analytics website athttp://www.poweranalytics.com
Story continues
Forward-Looking Statements:The above news release contains forward-looking statements. The statements contained in this document that are not statements of historical fact, including but not limited to, statements identified by the use of terms such as "anticipate," "appear," "believe," "could," "estimate," "expect," "hope," "indicate," "intend," "likely," "may," "might," "plan," "potential," "project," "seek," "should," "will," "would," and other variations or negative expressions of these terms, including statements related to expected market trends and the Company's performance, are all "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve a number of risks and uncertainties. These statements are based on assumptions that management believes are reasonable based on currently available information, and include statements regarding the intent, belief or current expectations of the Company and its management. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performances and are subject to a wide range of external factors, uncertainties, business risks, and other risks identified in filings made by the company with the Securities and Exchange Commission. Actual results may differ materially from those indicated by such forward-looking statements. The Company expressly disclaims any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company's expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based except as required by applicable law and regulations.
InvestorRelationsDamon CameronPower Analytics Global201.280.9850dcameron@poweranalytics.com
Recommendation and review posted by Bethany Smith
Antioxidant Supplement Market Comprehensive Insights and Forecast 2019 to 2025 – Galus Australis
The report titled Antioxidant Supplement Market has recently added by MarketInsightsReports to get a stronger and effective business outlook. It provides an in-depth analysis of different attributes of industries such as trends, policies, and clients operating in several regions. The qualitative and quantitative analysis techniques have been used by analysts to provide accurate and applicable data to the readers, business owners and industry experts.
Get a sample copy before purchase:
The report presents the market competitive landscape and a corresponding detailed analysis of the major vendor/key players in the market. Top Companies in the Global Antioxidant Supplement Market: NOW, Vibrant Health, AST R-ALA, GNC, Jarrow Formulas, Life Extension and other
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key players and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Global Antioxidant Supplement Market Split By Product Type And Applications:
This report segments the global Antioxidant Supplement Market on the basis ofTypesare:
Medical GradeFood Grade
On the basis ofApplication, the Global Antioxidant Supplement Market is segmented into:
MedicalFoodCosmetics
Regional Analysis for Antioxidant Supplement Market:
For comprehensive understanding of market dynamics, the global Antioxidant Supplement Market is analyzed across key geographies namely: United States, China, Europe, Japan, Middle East & Africa, India, and others. Each of these regions is analyzed on basis of market findings across major countries in these regions for a macro-level understanding of the market.
-Comprehensive assessment of all opportunities and risk in the Antioxidant Supplement Market.
Antioxidant Supplement Market recent innovations and major events.
-Detailed study of business strategies for growth of the Antioxidant Supplement Market -leading players.
-Conclusive study about the growth plot of Antioxidant Supplement Market for forthcoming years.
-In-depth understanding of Antioxidant Supplement Market -particular drivers, constraints and major micro markets.
-Favourable impression inside vital technological and market latest trends striking the Antioxidant Supplement Market.
Explore Full Report With Detailed TOC Here:
Finally, Antioxidant Supplement Market report is the believable source for gaining the Market research that will exponentially accelerate your business. The report gives the principle locale, economic situations with the item value, benefit, limit, generation, supply, request and Market development rate and figure and so on. This report additionally Present new task SWOT examination, speculation attainability investigation, and venture return investigation.
Customization of the Report:This report can be customized as per your needs for additional data up to 3 companies or countries or 40 analyst hours.
Please connect with our sales team (sales@marketinsightsreports.com)
About Us:
MarketInsightsReports provides syndicated market research on industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. MarketInsightsReports provides global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.
Contact Us:
Irfan Tamboli (Head of Sales) Market Insights Reports
Phone: + 1704 266 3234 | +91-750-707-8687
sales@marketinsightsreports.com | irfan@marketinsightsreports.com
Original post:
Antioxidant Supplement Market Comprehensive Insights and Forecast 2019 to 2025 - Galus Australis
Recommendation and review posted by Bethany Smith
Does an apple a day really keep the doctor away? The health myths that are just that – The Independent
Questionable nutritional advice is easily amplified in our digital world, but older generations have always passed down health adages that younger generations found difficult to believe. Did your parents ever encourage you to drink fish oil to boost brain power before an exam, or offer mustard when you had a muscle cramp? My folks believed ginger relieves nausea. I was curious whether these adages and folk remedies could withstand the scrutiny of science or whether theyre bunkum. So I set out to research a few of them.
An apple a day keeps the doctor away
This well-known statement is based on an 1860s Welsh proverb that eating apples will diminish doctor visits. And it has actually been put to the test in a 2015 April FoolsDay issue of JAMA Internal Medicine (while the topics were zany, the studies were real).
From 15p 0.18 $0.18 USD 0.27 a day, more exclusives, analysis and extras.
Researchers investigated whether people who reported eating apples daily actually had fewer annual doctor visits or were in better overall health. Of the 8,399 study participants, 753 ate at least one small apple daily. The results showed that 39 per cent of apple eaters avoided physician visits compared to 34 per cent of non-apple eaters, which was not a statistically significant difference. Researchers did find that apple eaters were a bit less likely to require prescription medications compared to non-apple eaters, leading the researcher to joke that an apple a day keeps the pharmacist away.
Jackdaws can identify dangerous humans from listening to each others warning calls, scientists say. The highly social birds will also remember that person if they come near their nests again, according to researchers from the University of Exeter. In the study, a person unknown to the wild jackdaws approached their nest. At the same time scientists played a recording of a warning call (threatening) or contact calls (non-threatening). The next time jackdaws saw this same person, the birds that had previously heard the warning call were defensive and returned to their nests more than twice as quickly on average.
Getty
The sex of the turtle is determined by the temperatures at which they are incubated. Warm temperatures favour females.But by wiggling around the egg, embryos can find the Goldilocks Zone which means they are able to shield themselves against extreme thermal conditions and produce a balanced sex ratio, according to the new study published in Current Biology journal
Ye et al/Current Biology
African elephant poaching rates have dropped by 60 per cent in six years, an international study has found. It is thought the decline could be associated with the ivory trade ban introduced in China in 2017.
Reuters
Scientists have identified a four-legged creature with webbed feet to be an ancestor of the whale. Fossils unearthed in Peru have led scientists to conclude that the enormous creatures that traverse the planets oceans today are descended from small hoofed ancestors that lived in south Asia 50 million years ago
A. Gennari
A scientist has stumbled upon a creature with a transient anus that appears only when it is needed, before vanishing completely. Dr Sidney Tamm of the Marine Biological Laboratory could not initially find any trace of an anus on the species. However, as the animal gets full, a pore opens up to dispose of waste
Steven G Johnson
Feared extinct, the Wallace's Giant bee has been spotted for the first time in nearly 40 years. An international team of conservationists spotted the bee, that is four times the size of a typical honeybee, on an expedition to a group of Indonesian Islands
Clay Bolt
Fossilised bones digested by crocodiles have revealed the existence of three new mammal species that roamed the Cayman Islands 300 years ago. The bones belonged to two large rodent species and a small shrew-like animal
New Mexico Museum of Natural History
Scientists at the University of Maryland have created a fabric that adapts to heat, expanding to allow more heat to escape the body when warm and compacting to retain more heat when cold
Faye Levine, University of Maryland
A study from the University of Tokyo has found that the tears of baby mice cause female mice to be less interested in the sexual advances of males
Getty
The Intergovernmental Panel on Climate Change has issued a report which projects the impact of a rise in global temperatures of 1.5 degrees Celsius and warns against a higher increase
Getty
The nobel prize for chemistry has been awarded to three chemists working with evolution. Frances Smith is being awarded the prize for her work on directing the evolution of enzymes, while Gregory Winter and George Smith take the prize for their work on phage display of peptides and antibodies
Getty/AFP
The nobel prize for physics has been awarded to three physicists working with lasers. Arthur Ashkin (L) was awarded for his "optical tweezers" which use lasers to grab particles, atoms, viruses and other living cells. Donna Strickland and Grard Mourou were jointly awarded the prize for developing chirped-pulse amplification of lasers
Reuters/AP
The Ledumahadi Mafube roamed around 200 million years ago in what is now South Africa. Recently discovered by a team of international scientists, it was the largest land animal of its time, weighing 12 tons and standing at 13 feet. In Sesotho, the South African language of the region in which the dinosaur was discovered, its name means "a giant thunderclap at dawn"
Viktor Radermacher / SWNS
Scientists have witnessed the birth of a planet for the first time ever. This spectacular image from the SPHERE instrument on ESO's Very Large Telescope is the first clear image of a planet caught in the very act of formation around the dwarf star PDS 70. The planet stands clearly out, visible as a bright point to the right of the center of the image, which is blacked out by the coronagraph mask used to block the blinding light of the central star.
ESO/A. Mller et al
Layers long thought to be dense, connective tissue are actually a series of fluid-filled compartments researchers have termed the interstitium. These compartments are found beneath the skin, as well as lining the gut, lungs, blood vessels and muscles, and join together to form a network supported by a mesh of strong, flexible proteins
Getty
Working in the Brazilian state of Mato Grosso, a team led by archaeologists at the University of Exeter unearthed hundreds of villages hidden in the depths of the rainforest. These excavations included evidence of fortifications and mysterious earthworks called geoglyphs
Jos Iriarte
More than one in 10 people were found to have traces of class A drugs on their fingers by scientists developing a new fingerprint-based drug test.Using sensitive analysis of the chemical composition of sweat, researchers were able to tell the difference between those who had been directly exposed to heroin and cocaine, and those who had encountered it indirectly.
Getty
The storm bigger than the Earth, has been swhirling for 350 years. The image's colours have been enhanced after it was sent back to Earth.
Pictures by: Tom Momary
Included in Wellcome Image Awards, this 3D image of an African grey parrot shows the highly intricate system of blood vessels.
Scott Birch. Wellcome Images
Another Wellcome Images Award winner, this time of baby Hawaiian bobtail squid. The black ink sac and light organ in the centre of the squids mantle cavity can be clearly seen.
Macroscopic Solutions. Wellcome Images
Jackdaws can identify dangerous humans from listening to each others warning calls, scientists say. The highly social birds will also remember that person if they come near their nests again, according to researchers from the University of Exeter. In the study, a person unknown to the wild jackdaws approached their nest. At the same time scientists played a recording of a warning call (threatening) or contact calls (non-threatening). The next time jackdaws saw this same person, the birds that had previously heard the warning call were defensive and returned to their nests more than twice as quickly on average.
Getty
The sex of the turtle is determined by the temperatures at which they are incubated. Warm temperatures favour females.But by wiggling around the egg, embryos can find the Goldilocks Zone which means they are able to shield themselves against extreme thermal conditions and produce a balanced sex ratio, according to the new study published in Current Biology journal
Ye et al/Current Biology
African elephant poaching rates have dropped by 60 per cent in six years, an international study has found. It is thought the decline could be associated with the ivory trade ban introduced in China in 2017.
Reuters
Scientists have identified a four-legged creature with webbed feet to be an ancestor of the whale. Fossils unearthed in Peru have led scientists to conclude that the enormous creatures that traverse the planets oceans today are descended from small hoofed ancestors that lived in south Asia 50 million years ago
A. Gennari
A scientist has stumbled upon a creature with a transient anus that appears only when it is needed, before vanishing completely. Dr Sidney Tamm of the Marine Biological Laboratory could not initially find any trace of an anus on the species. However, as the animal gets full, a pore opens up to dispose of waste
Steven G Johnson
Feared extinct, the Wallace's Giant bee has been spotted for the first time in nearly 40 years. An international team of conservationists spotted the bee, that is four times the size of a typical honeybee, on an expedition to a group of Indonesian Islands
Clay Bolt
Fossilised bones digested by crocodiles have revealed the existence of three new mammal species that roamed the Cayman Islands 300 years ago. The bones belonged to two large rodent species and a small shrew-like animal
New Mexico Museum of Natural History
Scientists at the University of Maryland have created a fabric that adapts to heat, expanding to allow more heat to escape the body when warm and compacting to retain more heat when cold
Faye Levine, University of Maryland
A study from the University of Tokyo has found that the tears of baby mice cause female mice to be less interested in the sexual advances of males
Getty
The Intergovernmental Panel on Climate Change has issued a report which projects the impact of a rise in global temperatures of 1.5 degrees Celsius and warns against a higher increase
Getty
The nobel prize for chemistry has been awarded to three chemists working with evolution. Frances Smith is being awarded the prize for her work on directing the evolution of enzymes, while Gregory Winter and George Smith take the prize for their work on phage display of peptides and antibodies
Getty/AFP
The nobel prize for physics has been awarded to three physicists working with lasers. Arthur Ashkin (L) was awarded for his "optical tweezers" which use lasers to grab particles, atoms, viruses and other living cells. Donna Strickland and Grard Mourou were jointly awarded the prize for developing chirped-pulse amplification of lasers
Reuters/AP
The Ledumahadi Mafube roamed around 200 million years ago in what is now South Africa. Recently discovered by a team of international scientists, it was the largest land animal of its time, weighing 12 tons and standing at 13 feet. In Sesotho, the South African language of the region in which the dinosaur was discovered, its name means "a giant thunderclap at dawn"
Viktor Radermacher / SWNS
Scientists have witnessed the birth of a planet for the first time ever. This spectacular image from the SPHERE instrument on ESO's Very Large Telescope is the first clear image of a planet caught in the very act of formation around the dwarf star PDS 70. The planet stands clearly out, visible as a bright point to the right of the center of the image, which is blacked out by the coronagraph mask used to block the blinding light of the central star.
ESO/A. Mller et al
Layers long thought to be dense, connective tissue are actually a series of fluid-filled compartments researchers have termed the interstitium. These compartments are found beneath the skin, as well as lining the gut, lungs, blood vessels and muscles, and join together to form a network supported by a mesh of strong, flexible proteins
Getty
Working in the Brazilian state of Mato Grosso, a team led by archaeologists at the University of Exeter unearthed hundreds of villages hidden in the depths of the rainforest. These excavations included evidence of fortifications and mysterious earthworks called geoglyphs
Jos Iriarte
More than one in 10 people were found to have traces of class A drugs on their fingers by scientists developing a new fingerprint-based drug test.Using sensitive analysis of the chemical composition of sweat, researchers were able to tell the difference between those who had been directly exposed to heroin and cocaine, and those who had encountered it indirectly.
Getty
The storm bigger than the Earth, has been swhirling for 350 years. The image's colours have been enhanced after it was sent back to Earth.
Pictures by: Tom Momary
Included in Wellcome Image Awards, this 3D image of an African grey parrot shows the highly intricate system of blood vessels.
Scott Birch. Wellcome Images
Another Wellcome Images Award winner, this time of baby Hawaiian bobtail squid. The black ink sac and light organ in the centre of the squids mantle cavity can be clearly seen.
Macroscopic Solutions. Wellcome Images
Of course, the doctor proverb shouldnt be taken literally, but the overall sentiment is true: eating vegetables and fruits daily does have health benefits. Thats because the combination of fibre, vitamins, minerals and phytonutrients may help reduce inflammation and combat cardiovascular disease and some types of cancer.
Carrots are good for your eyes
This narrative traces back to the SecondWorld War. In 1940, British royal air force pilots began using radar to shoot down enemy planes in the dark. To keep this new technology a secret, the Ministry of Informations propaganda was that the pilots had great visual accuracy because they ate carrots, which improved their night vision.
Many children have to be threatened with the possibility of poor eyesightbefore they eat their carrots(Getty)
It seemed plausible, too, because carrots are rich in the antioxidant beta carotene, the precursor to vitamin A. Once absorbed by the body, vitamin A helps make rhodopsin, a pigment that helps eyes work better in low light. Carrots can help if you have vitamin A deficiency that causes poor night vision, but of course they cant really help you (or air force pilots) see in complete darkness. So, yes, carrots are good for eyesight, but other foods rich in beta carotene, such as sweet potatoes, squash and leafy green vegetables, have the same benefits.
Turkey makes you tired
Weve all heard this one after Christmas dinner: The turkey made you fall asleep! Turkey contains an amino acid (a building block of protein) known as tryptophan, which the body uses to generate serotonin, which helps promote sleep. So then there must be something to this whole turkey-sleep connection, right?
Not so fast. Turkey contains no more tryptophan than beef, eggs, fish or chicken, and tryptophan has a hard time getting past the blood-brain barrier, so its not an effective sleep inducer on its own. But the effect of tryptophan increases when insulin levels are high, as happens after you eat a carb-rich meal such as a Christmasdinner with stuffing andpotatoes. So its actually carbs that increase serotonin levels and help with the production of the hormone melatonin, which makes you sleepy. Eating a large meal can have a similar effect because theres increased blood flow to the stomach for digestion, and decreased blood flow to the brain. So its definitely not just turkey that makes you sleepy.
Ginger is also believed to help chronic indigestion and muscle pain (Getty)
Ginger relieves nausea
This remedy has strong roots. More than 5,000 years ago, people from India and China used ginger as a tonic to treat many ailments. The most common and well-established historical use is to alleviate nausea and vomiting. Today, many clinical studies support the use of ginger for exactly this purpose.
Research shows that ginger helps relieve nausea and vomiting caused by motion sickness, morning sickness in pregnancy, during chemotherapy treatments and post-surgically after anaesthetic. Its thought that the constituents in ginger including gingerols and shogaols help speed gastric emptying, which relieves nausea. Some people sip ginger tea for relief, while others prefer to take a ginger capsule, and studies show that both options can work. My mum used to open a can of ginger ale when I was queasy. While she was on the right track, it turns out many soda brands use artificial flavouring rather than real ginger, so those are of little benefit.
Only the best news in your inbox
Fish can be one of the most diverse and budget-friendly proteins (Getty)
Fish is good for your brain
The rest is here:
Does an apple a day really keep the doctor away? The health myths that are just that - The Independent
Recommendation and review posted by Bethany Smith
Thyroid function test: Know what T3, T4 and TSH mean – Times of India
If you are feeling lethargic or anxious and have gained weight, your doctor might recommend a thyroid function test. These are a series of blood tests that are used to measure how the thyroid gland is functioning. Thyroid hormone affects a persons physical energy, temperature, weight and mood.An estimated 42 million people in India suffer from thyroid diseases, so it is important to get a thyroid function test, especially if you are in the high risk category. Women and old people are at a higher risk of hypothyroidism.What are thyroid function tests?
The thyroid gland produces thyroid hormones triiodothyronine (T3) and thyroxine T4) and a thyroid function test is recommended to assess the levels of these two hormones.
The thyroid panel (test package) also includes a test for thyroid stimulating hormone (TSH), which is produced by the pituitary gland. This hormone helps in regulating the hormones produced by the thyroid gland.
A TSH test is used to determine the underlying cause of abnormal thyroid hormone levels. It is also used to screen for an underactive or overactive thyroid gland.
Are you at risk of thyroid?
T4 and TSH tests are routinely performed on newborns to identify low-functioning thyroid gland. If you are 35 and above or have any risk factors of thyroid disease, it is advised to undergo a screening for thyroid every five years or as prescribed by your doctor.
In addition to high-risk groups, doctors may recommend thyroid screening for patients:
-With a swollen neck (due to an enlarged thyroid gland).-Who have had surgery or radiation therapy, which might have affected the thyroid gland.-With Type 1 Diabetes Mellitus.-With family history of autoimmune thyroid disease.-With psychiatric disorders.-With Downs or Turner Syndrome.
What is the normal range of T3, T4 and TSH?T3: 100200 nanograms per deciliter of blood (ng/dL)
T4: 4.5 11.2 micrograms per deciliter of blood (mcg/dL)
TSH: 0.4 5.0 milli-international units per liter (mIU/dL)
However, if you already have thyroid disease, then the normal range of TSH should be 0.5 3.0 milli-international units per liter.
Overnight fasting is required before undergoing the test. Also, if you are on steroids or taking oral contraceptives, inform your doctor about the same as it might interfere with the test reports.
Understanding the test resultsUsually, T4 and TSH results are used to derive at a diagnosis. However, T3 can help if T4 and TSH suggest hyperthyroidism or if your thyroid levels are not elevated but you might be showing signs and symptoms of hyperthyroidism.
Patterns of thyroid function tests during an assessment of thyroid function are:
Normal thyroid (Euthyroid)
T3: Normal
T4: Normal
TSH: Normal
Overactive thyroid (hyperthyroidism)
T3: High
T4: High or normal
TSH: Low
Underactive thyroid (hypothyroidism)
T3: Normal or low
T4: Low
TSH: High
Thyroid tests next steps
If the test reports are normal, even then diet modifications such as vitamin and mineral supplements may be recommended by your doctor.
DISCLAIMER:This article is authored and provided by The Times of India Healthy India Fit India partner, 1mg.
Continued here:
Thyroid function test: Know what T3, T4 and TSH mean - Times of India
Recommendation and review posted by Bethany Smith
Dogs reduce distress of patients waiting for emergency hospital care – Jill Lopez
A visit from a dog can reduce the distress of patients waiting for emergency treatment in hospital, a study by the University of Saskatchewan (USask) shows.
Patients who spent 10 minutes with a visiting therapy dog--a four-year-old springer spaniel named Murphy--reported they felt more comfortable, happier and less distressed while waiting for emergency care in hospital.
The study, published in thePatient Experience Journal, found a significant increase in comfort levels and positive feelings after spending time petting, cuddling or interacting with the experienced canine.
The study was carried out at the Royal University Hospital (RUH) in Saskatoon, Saskatchewan--the first emergency department in Canada to introduce therapy dogs to improve the experience of waiting patients.
There is growing evidence that therapy or comfort dogs can be beneficial to human health and can reduce anxiety, heart rate and blood pressure. Interaction with a dog increases production of dopamine, a neurotransmitter, which reduces the stress hormone cortisol.
Professor Colleen Dell, Research Chair in One Health & Wellness at USask's College of Arts and Science, co-led the study with emergency physician Dr. James Stempien, MD, Provincial Department Head, Emergency Medicine in Saskatchewan. The research was supported by the Saskatchewan Centre for Patient-Oriented Research.
"Emergency departments are hectic and confusing places. Most people waiting for treatment feel nervous, and waiting can increase their pain. It is well-known that interacting with animals can help humans feel calm and relaxed. Our study showed a noticeable improvement in the patient's mood after interacting with a therapy dog," Dell said.
"With waiting times consistently high in emergency departments, it suggests that therapy dogs may have a broader therapeutic role to play comforting patients in distress and pain."
RUH is the first emergency department in Canada to allow therapy dogs to visit, with up to six trained therapy dogs now visiting several days a week.
Patients met the dog for between 10 and 30 minutes and included people with cardiac complaints, fractures, psychiatric issues, and those suffering chronic pain.
The 124 patients were waiting in curtained-off cubicles and found their distress levels decreased, and their perceived comfort levels increased after interacting with the spaniel, a certified St. John Ambulance Therapy Dog and its handler. The distress of patients meeting Murphy decreased regardless of the length of their wait.
Patients filled out questionnaires about their well-being and feelings before and after meeting Murphy. The most common themes were feeling 'happy', 'okay', 'better' and 'calm', and 80 per cent expressed happiness during the visit and said they felt calmer after the visit.
Sixty six per cent of those visited by Murphy patted him, stroked him or cuddled him. One patient gave the dog a massage and some snuggled up to him or let the dog put his head on their chest. In almost a quarter of cases, the dog's 'intuition' when interacting with a patient was noted.
Logan Fele-Slaferek, a co-author of the paper and patient advocate, met Murphy on several occasions while an RUH inpatient for a recurrent health condition. On one occasion, after a six-month-long treatment program had failed and he was feeling 'crushed and hopeless', the spaniel jumped on Logan's lap and fell asleep.
"I was a little skeptical about his helping at first, but that all changed five minutes later. The dog picks up on your mood or temperament better than most people would. He helped my recovery immensely. It's something about being next to an animal that exudes nothing but love and kindness," Fele-Slaferek, an undergraduate at USask, said. "The emergency department can be so hectic, but time slows down when you are with a therapy dog. His presence is soothing."
Jane Smith, Murphy's handler, said it is clear the therapy dog enjoys meeting the patients, and sometimes does not want to leave them.
"When Murphy enters the emergency department, the mood changes quickly. You can see patients, doctors, and staff smiling, even before he actually visits anyone," she said. "During the visits he looks at patients with big, brown eyes, settling in to enjoy the pets and cuddles. Sometimes, Murphy needs extra encouragement to leave a patient. It is actually hard to tell who enjoys the visit more."
This preliminary study has led to Dell and her team being awarded a research grant of $20,000 from the Royal University Hospital Foundation to undertake further research at RUH into the impact of therapy dog visits on adult emergency department patients and their experiences of pain.
Read more here:
Dogs reduce distress of patients waiting for emergency hospital care - Jill Lopez
Recommendation and review posted by Bethany Smith
Planned Parenthood didn’t tell her she was pregnant with twins. Then, they survived the abortion pill. – Live Action News
(Pregnancy Help News) Recently, a Tennessee woman gave birth to healthy twin babies who miraculously survived a chemical abortion attempt at a Knoxville, TN, Planned Parenthood.
The incredible story of these miracle babies, as told by one pro-life physician, underscores just how sorely the abortion giant fails to meet the needs of women, both from a medical standpoint and a human one.
Displaying obvious ineptitude from the start, the nations largest abortion business only informed the woman she was pregnant with twins after the chemical abortion shed been given by Planned Parenthood staff failed.
Furthermore, at her initial visit to the Planned Parenthood facility, the staff misinformed her about the basic biological development happening within her seven-week pregnancy, stating that it was too early for a heartbeat and that it was just cardiac activity they were seeing.
Pro-life physician Brent Boles, who helped the woman following her failed abortion, commented on Facebook earlier this month about the twins birth and Planned Parenthoods handling of the pregnancy.
Abortion isnt about caring for the woman, Boles said. Its about the $$$.
Boles had originally shared the story on the social media platform this past March after the woman contacted him looking for help.
Boles, who is a member of the Abortion Pill Rescue Network, told Pregnancy Help News that his patient originally came to him through the groups 24/7 helpline (877-558-0333). She had found the helpline after returning to Planned Parenthood for a follow-up appointment and discovering that she was still pregnant.
READ:Pro-choice? Media slams miscarriage-halting hormone when used to reverse the abortion pill
Because Planned Parenthood had no help to offer her, she left and scoured the web before landing on AbortionPillReversal.com.
From the doctors October 4 post:
Earlier this year, a patient called the Abortion Pill Rescue hotline and was referred to me. Three weeks before, she had been in a Planned Parenthood facility. She had an ultrasound at seven weeks, and asked during the ultrasound if there was a heartbeat. She was told No, its too early to call it a heartbeat; it is just cardiac activity.
As he did in his Facebook post this past March, Boles lambasted the abortion industry cardiac activity lie in his new post about the twins:
Problem #1: those types of statements are just deceptive word games. Calling the fetal heartbeat embryonic pulsing or cardiac activity and saying that it is not yet a heartbeat is a lie. The leading textbooks of embryology say that the heart begins to beat at five weeks and they call that a heartbeat. No medical or scientific text affirms their erroneous concept that pulsatile activity is not yet a heartbeat. In fact, those texts say that the cardiac/circulatory system is the first organ system to perform its adult purpose in utero. They lied to her in order to have her emotionally commit to handing over her cash and having the abortion.
That wasnt the only problem with Planned Parenthoods so-called medical evaluation of his patient:
Problem #2: at seven weeks the vast majority of competent sonographers will never miss twins at that point. But women who find out they are having twins are far less likely to abort twins, as the thought of aborting only one baby does t seem quite as bad as aborting two. So either an incompetent sonographer missed the fact that she had twins or didnt want to tell her and have her thousand dollars walk out the door with her.
She did the course of the abortion pill and nothing happened. She went back two weeks later and had another ultrasound at approximately nine weeks and they said oh well, it didnt work, and you are having twins. She asked what could be done and they said nothing. She left, found the number to call on google, and that led her to my office.
Abortion Pill Reversal, which has saved more than 900 babies to date, works by giving pregnant women additional progesterone, a natural hormone that sustains a healthy pregnancy. In the case of a twin pregnancy, a womans body produces more progesterone to nurture both babies.
In evaluating his patient and the twins, Boles determined that in this case, extra progesterone via Abortion Pill Reversal wouldnt be necessary. But for Boles, that still didnt excuse Planned Parenthoods glaring incompetence when it came to administering a practice he strongly opposes:
Problem #3: they (Planned Parenthood) dont even know how to use the medication properly, assuming they did know it was twins. I am prolife and I know that a higher dose of mifeprex is required to work successfully to abort a multiple gestation, because a twin pregnancy produces higher levels of progesterone.
For Christa Brown, director of Medical Impact at Heartbeat International, the twins survival, as well as other survivals achieved through the Abortion Pill Rescue Network, marks a notable victory for life.
Its incredible to think that the abortion industry has already counted those babies as abortion statistics, but instead they are alive and well, she said. We are so thankful for Dr. Boles and all of the providers in the Abortion Pill Rescue Network who are saving lives every single day worldwide. To date, the abortion industry has lost nearly 1,000 of their statistics and our world has gained nearly 1,000 precious babies who are growing and thriving thanks to the APR Network.
Not only did Planned Parenthood fail this woman in every medical aspect, but the abortion business also failed to meet her basic human needs as a pregnant woman now expecting twins. Boless final critique of the abortion giant?
Problem #4: they refused to offer any advice or counsel.
For several years now, abortion advocates have fired off endless lies about the help provided by pro-life pregnancy help organizations. But who is really taking care of women in unexpected pregnancies?
More than 2,750 pregnancy help centers all across the U.S. are providing counsel and resources to women in need every day. From diapers to housing to parenting classes to free obstetrical ultrasound scans, they are serving families from a place of utmost compassion and care.
READ:Abortion pill reversal saved her baby after she regretted taking the first dose
In 2017, they served nearly 2 million clients, saving communities, an estimated $161 million.
When the abortion industry fails to meet womens needs, pregnancy centers are there. When a woman is kicked out of her home and has nowhere to go, maternity homes are there. When the abortion industry leaves a woman grieving and regretting her choice, abortion recovery ministries are there.
When a woman desperately wants to save her unborn child from an in-process chemical abortion, Dr. Boles and hundreds of other pro-life physicians in the Abortion Pill Rescue Network are there, offering her child one last chance at life.
Despite Planned Parenthoods utter failure to meet this patients needs, today two healthy babies are alive and doing well in the state of Tennessee.
These twins have now delivered at term, uncomplicated by any other issues, Boles wrote in his social media post, and are at home with their parents, who are exceedingly pleased that a decision made under pressure and while in fear did not work out as planned.
PHN Editors note: The AbortionPillReversal.com program, the Abortion Pill Rescue Network (APRN) and Pregnancy Help News are managed by Heartbeat International.
Editors Note: This article was printed at Pregnancy Help News and is reprinted here with permission.
Like Live Action News on Facebookfor more pro-life news and commentary!
Recommendation and review posted by Bethany Smith